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ABSTRACT 
 
 
The abuse of and addiction to drugs of abuse, such as tobacco, alcohol, opioids, 
and illicit drugs, are growing global problems that affect the welfare of individuals and 
societies worldwide. The National Institute of Drug Abuse estimates the annual cost of 
substance abuse to be over $740 billion in costs related to drug intoxication, withdrawal 
and relapse. A primary challenge in the treatment of substance abuse is the tendency of 
users to relapse following acute or extended periods of abstinence; on average over 60% 
of substance abusers will return to drug use within a year of receiving treatment, many 
relapsing following stressful life events. Central to the successful treatment of drug 
addiction is understanding the cellular mechanisms by which relapse episodes occur. 
Current data suggest that the activation of pituitary adenylate cyclase activating peptide 
(PACAP) systems in the bed nucleus of the stria terminalis (BNST) is an important event 
underlying stress-induced reinstatement to drug-seeking in a rodent model of stress-
induced relapse. 
 
In conjunction with immunohistochemistry and pharmacological treatments, we 
used this behavioral model of stress-induced relapse to evaluate PACAP and PACAP 
type-1 receptor (PAC1-R) signaling in stress-induced reinstatement to cocaine seeking. 
Activation of the PAC1 receptor appears to be critical to stress-induced reinstatement, as 
the selective PAC1-R agonist, maxadilan, produced reinstatement behaviors in the 
absence of stress. Moreover, BNST pretreatment with either mitogen activated protein 
kinase-ERK (MEK) or endocytosis inhibitors to block extracellular signal-related kinase 
(ERK) signaling attenuated stress-induced reinstatement. Furthermore, BNST 
phosphorylated ERK (pERK) expression, mediated by PAC1-R activation, is 
substantially potentiated in cocaine-experienced animals after stressor exposure, in a 
manner that is dependent on endosomal signaling and MEK activity.  
 
These data suggest that the activation of a PAC1 signaling cascade is a key event 
underlying stress-induced reinstatement. Furthermore, this data may suggest a permanent 
change in the BNST PACAP system (sensitization) following cocaine exposure. 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1. General Introduction 
 
The abuse of and addiction to drugs of abuse, such as tobacco, alcohol, opioids, and 
illicit drugs is a growing global problem that affects the welfare of individuals and 
societies worldwide. Indeed, substance abuse is costly to the Unites States: the National 
Institute of Drug Abuse estimates expenditures of $740 billion annually on costs related 
to drug intoxication, withdrawal, relapse (Feit & Taylor, 2015), and the consequences 
of this chronic cycle. 
 
A primary challenge in the treatment of substance abuse is the tendency of users to 
relapse following acute or extended periods of abstinence. On average, over 60% of 
substance abusers will return to drug use within a year of receiving treatment (Scott et 
al., 2011; Higgins et al., 2012). Although many factors may contribute to drug relapse, 
one critical factor may be exposure to a stressor (Sinha et al., 2006). Relapse rates are 
often higher following stressful events (Breese et al., 2011). In laboratory settings, 
stressors can produce the “reinstatement” of drug-seeking behaviors following periods 
of abstinence. In a standard stress-induced reinstatement procedure (discussed in detail 
below), rats self-administer cocaine via lever-press response, and then have the 
behavior extinguished, where subsequent lever presses no longer deliver cocaine. After 
extinction, exposure to a stressor (i.e. unpredictable footshock) can reinstate drug-
seeking on the lever previously associated with cocaine delivery. Reinstatement of 
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drug-seeking has also been observed after re-exposure to the drug (drug priming), drug 
cues, or intermittent stressor exposure (Miles et al., 2017; Mantsch et al., 2015; Erb & 
Stewart, 1999; Carroll & Comer, 1996). In virtually all models of addiction, drugs have 
been shown to simultaneously activate both reward and stress circuits, and while stress 
itself may cause relapse, the underlying mechanisms are unclear. However, the 
activation of central and peripheral stress responses likely becomes a part of the context 
or drug taking. Stress might therefore create a “renewal effect” and cause relapse of 
responding when it occurs again after extinction has been conducted in the absence of 
stress (see Bouton, 2014; Schepers, 2017; Miles et al., 2017), which has been called the 
contextual hypothesis of stress-induced reinstatement. Upon stressor exposure, several 
stress response systems are activated, including the hypothalamic pituitary adrenal 
(HPA) axis and the sympathetic nervous system (SNS), as well as neural circuits 
important for emotional behavior such as fear and anxiety. Brain areas involved in 
regulating these physiological and emotional processes may undergo neurochemical 
and morphological changes following stressor exposure. These changes may underlie 
several mental health disorders (such as post-traumatic stress disorder (PTSD) and 
depression; Hammack et al., 2010) including relapse to drug use. Indeed, the activation 
of these systems may also be critical to both the maintenance and relapse of addiction.  
 
During a stress-induced reinstatement paradigm, stressor exposure activates the HPA 
axis, a central circuit that serves to maintain an organism’s homeostasis by promoting 
necessary changes in physiological and behavioral responses to a stimulus. This action 
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is dependent on corticotropin-releasing hormone (CRH) release (Tsigos & Chrousos, 
2002). However, CRH activation in extra-hypothalamic brain regions, including the 
amygdala and bed nucleus of the stria terminalis (BNST) may mediate some of the 
behavioral and physiological symptoms of stressor exposure, including stress-induced 
relapse.  
 
The BNST has been linked to anxiety- and stress-responding in both clinical and 
laboratory settings (Avery et al., 2016; Walker et al., 2003). Hence, the structure has 
been implicated in numerous neurochemical, morphological and physiological 
alterations after stressor exposure (Dumont et al., 2008) that enhance BNST function 
and mediate stress-related consequences. A heterogeneous structure, activity in the 
BNST may be critical for creating and maintaining these alterations long-term. The 
BNST has been subdivided into different sub-regions based on neuronal morphology, 
afferent and efferent connections, and neurochemistry (see below; Avery et al., 2016). 
Moreover, neurons within the BNST express numerous receptor subtypes that bind 
multiple neuropeptides, such as CRH (Ch’ng et al., 2018), neurotensin (Moga et al., 
1985), and enkephalin (Haber et al., 1983), among others. This heterogeneity, and the 
neuropeptides present, suggests that the regulation of BNST activity is complex (see 
Figure 1.5). Several researchers have implicated the BNST oval nucleus in the 
mediation of emotional (i.e. stressful) responses (Daniel & Rannie, 2016). Indeed, the 
BNST oval nucleus (BNSTov), in addition to containing its own endogenous CRH, 
receives CRH inputs from the central amygdala (CeA; an area responsible for 
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autonomic and behavioral components of emotion), and the basolateral amygdala 
(BLA; necessary for eliciting fear response) and parabrachial nucleus (PBn), 
hippocampus, and medial prefrontal cortex (mPFC), and also projects toward the 
paraventricular nucleus (PVN; in the hypothalamus), limbic structures and brainstem 
nuclei that mediate emotional behavior (Crestani et al., 2013). The BNST is thought to 
aid communication between limbic system structures and emotional processing 
systems, as the structure projects to and receives projections from areas responsible for 
both emotional and physiological responses to a stressor, and therefore may be 
prominent in mediating stress disorders (i.e. stress induced relapse; Roman et al., 2014; 
Hammack & May, 2015). Furthermore, the BNST may not only be activated by stressor 
exposure but may undergo physiological alterations as a result of stressor exposure 
(Lezak et al., 2014); hence, its neurochemistry and morphology is altered with repeated 
exposure to stress. In a study of unpredictable stress in rats, several researchers 
observed an increase in BNST volume and behavioral manifestations of stress (i.e. 
anxiety-like behavior) after 28 days of chronic stressor exposure (Pego et al., 2008; 
McEwen & Chattarji, 2007). However, it is important to note that certain sub-regions of 
the BNST may be more receptive to prolonged stressor exposure and have greater 
morphological and physiological changes than anatomically similar sub-regions. For 
example, our laboratory has observed alterations in pituitary adenylate cyclase-
activating peptide (PACAP) and its cognate receptor, PAC1, mRNA levels in the 
anterior dorsolateral BNST (BNSTld), but not the ventral BNST (vBNST), following a 
repeated variate stress paradigm in rats (Hammack et al., 2009). Additionally, several 
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research teams have observed increases in CRH following the same stress paradigm in 
the BNSTld, but not other regions of the BNST – changes that the researchers linked to 
an increase in anxiety-like behavior (Lee & Davis, 1997; Schulkin et al., 1998). Hence, 
stressor exposure and activation of the HPA axis may be linked to PACAP and CRH 
signaling in the BNST. 
 
In females, circulating PACAP levels are correlated with PTSD symptomology and 
anxiety-related disorders (see Ressler et al., 2011). As individuals with anxiety-
spectrum disorders often have maladaptive responses to stress, it reasons that PACAP 
levels will correlate to multiple stress-related disorders, including relapse to drug use. 
Indeed, there are high levels of comorbidity between individuals who abuse substances 
and those who present signs of anxiety-related disorders. PACAP has been implicated 
as a key regulator of signaling in stress-related brain regions (Hammack & May, 2015; 
Stroth et al., 2011). A neurotrophic factor, PACAP promotes cell survival of multiple 
neuron types, including progenitor cells, dorsal root ganglion cells, cerebellar granule 
cells, and peripheral sympathetic neurons (Stroth et al., 2011). Importantly, PACAP has 
been shown to increase cell survival in response to stressor exposure (Stroth et al., 
2013). Our laboratory and others have argued that PACAP plays a crucial role in stress 
responding (for review, see Hammack et al., 2010; Lezak et al., 2014; Mustafa et al., 
2015; Missig et al., 2014). Hence, PACAP may also play an important role in addiction 
processes. Indeed, addiction, or substance abuse, is itself a chronic stressor, and as 
noted above, many addiction processes may be regulated by stressor exposure. To 
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further understand the role of stress-related peptides on reinstatement processes, we 
investigated whether BNST PACAP was, first, necessary and sufficient for the 
behavioral properties of stress-induced reinstatement. Next, we examined the 
downstream intracellular mechanisms involved in this reinstatement process. In short, 
these investigations were aimed at understanding the molecular and anatomical 
substrates underlying the relationship between drug-seeking and stress. 
 
The remainder of this introduction is divided into three main sections: 1) neurobiology 
of addiction – reviewing the development, maintenance, and relapse phases of 
addiction; 2) BNST and its function in addiction processes; and 3) PACAP signaling in 
stress-induced reinstatement. The subsequent chapters are primary research studies in 
manuscript form, followed by a comprehensive discussion.  
 
1.2. Neurobiology of “Addiction” 
 
Characterization of Substance Abuse 
 The new Diagnostic and Statistical Manual of Mental Disorders (DSM)-V establishes 
diagnostic criteria for two distinct substance related issues: substance use disorders 
(addiction), and substance-induced disorders. Diagnosis of substance use disorders is 
based upon a pathological set of behaviors related to the use of a given substance: 
impaired control, social impairment, risky use, and pharmacological indicators (i.e. 
tolerance, withdrawal). For many, the pharmacological indicators that arise as a result 
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of continued use are key indicators of addiction. 
 
Substance abuse is typically characterized by recurring episodes of relapse following 
extended drug-free periods (Koob & Volkow, 2010; Erb, Shaham, & Stewart, 1998). 
The debilitating condition represents a state whereby drug seeking, and subsequent self-
administration, dominate the user’s thoughts and behaviors. For some individuals, the 
tendency to abuse drugs continues despite detrimental side effects, such as health 
problems and lost work productivity (Feit & Taylor, 2015). While some argue that 
substance abuse represents a loss of self-control (Charbogne, Kieffer & Befort, 2014), 
others view addiction as a maladaptive neural plasticity caused by exposure to drugs of 
abuse (Feng & Nestler, 2013), although it is unlikely that these views are mutually 
exclusive, as loss of self-control and changes in neural plasticity may complement each 
other. Hence, multiple factors contribute to substance abuse, including the disordered 
regulation of reward systems, environmental stimuli, and vulnerable genes (Jasinska et 
al., 2014; Levran et al., 2014). As mentioned, the tendency of users to relapse severely 
hinders the adequate treatment of substance abuse disorders. Understanding the 
behavioral and physiological mechanisms of relapse processes in substance abuse 
disorders is critical to determine viable targets for relapse prevention. 
 
Development of Addiction 
 Initial investigations of the neurobiology of addiction focused on acute impacts of 
drugs of abuse (i.e. physiological effects of a single injection of cocaine). However, 
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in the past several years, the investigative focus has shifted to observing the effects of 
chronic administration on brain changes that could lead to relapse (Koob & Volkow, 
2010). Indeed, chronic administration is one of the behavioral phenomenon 
characterizing the transition from casual drug use to addiction, as noted within the 
DSM criteria: “The substance is often taken in larger amounts over a longer period than 
was intended” (American Psychiatric Association, 2013). Hence, research in animal 
models has utilized two distinct methods of drug-administration to investigate neural 
circuits associated with continued drug use. The first, involving experimenter-
administered drug, explores the effects of continued drug presence on neurocircuits 
involved in addiction (discussed below). Here, behavioral sensitization to the drug is 
typically tested in the form of locomotion: animals who receive drug demonstrate 
increased responding on test day in response to stress (Seo et al., 2018) or priming 
injections (for example, see Blanco et al., 2015) compared to those who receive control 
treatment. The second, involving prolonged access to self-administration of drugs, may 
have more face validity to human drug-use, but could reflect a sensitization of reward, 
or a reward-deficit state (see Vezina, 2004). Here, extended access to drugs results in 
increased drug-taking over time, allowing researchers to study the effects of 
reinstatement (Miles et al., 2017), latency to goal time in a runway model for drug 
reward (Deroche-Gamonet et al., 2004), animals’ willingness to obtain the drug despite 
adverse events (Vanderschuren & Everitt, 2004), and the ability of a drug to support 
place preference in a conditioned place preference model. Both the experimental-
administered drug model and the animal self-administration model have helped 
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researchers gain a better understanding of the neurobiological substrates for the 
reinforcing (i.e. binge/intoxication), negative affect (i.e. withdrawal), and anticipation 
(i.e. craving) stages of addiction. 
 
Reinforcement Stage: Olds & Milner (1954) identified a reward system in the brain 
after recognizing that rodents would self-administer electrical stimulation to the ventral 
tegmental area (VTA). Importantly, rats would continually lever press in order to 
receive a brief electrical pulse into the septal region. Continued research in this area 
revealed a role of the medial forebrain bundle in reward processing, particularly when 
the reward involved norepinephrine (NE; Stein & Himwich, 1962) or dopamine (DA; 
Wise, 1978; Koob & Volkow, 2010) release. Indeed, mesolimbic dopamine is critical 
for acute, rewarding effects of drugs of abuse (see Robinson & Berridge, 1993; Schultz, 
2007). However, different drugs of abuse may activate specific brain regions: animals 
will directly administer opioids and alcohol into the VTA (Gatto et al., 1994; Koob & 
Volkow, 2010), psychostimulants into the nucleus accumbens (NAcc), and cocaine into 
the frontal cortex (McBride et al., 1999). The CeA also demonstrates a key negative-
reinforcement function in the acute reinforcing effects of drugs of abuse. Intra-CeA 
infusion of dopamine D1 receptor antagonists blocks cocaine self-administration (Caine 
et al., 1995), and lesions of the CeA block oral alcohol consumption (Möller et al., 
1997). As the CeA and BNST share similar morphologies, and are in close proximity, 
we and others have suggested that the BNST may also contribute to negative 
reinforcement of drug taking. Indeed, BNST lesions attenuate drug-seeking, and 
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activation causes reinstatement after periods of extinction.  Finally, as the ventral 
pallidum (VP) is a key target of nucleus accumbens and drug reward, blockade of 
dopamine and GABA receptors in this region blocks the reinforcing effects of acute 
alcohol intake (Rodd et al., 2014). Thus, drugs of abuse appear to activate regions 
within the mesolimbic dopamine system, and these regions may be critical to the acute 
reinforcing effects of drugs.  
 
Withdrawal Stage: While many brain regions are likely responsible for different aspects 
of withdrawal, a critical anatomical substrate may be the extended amygdala – a region 
comprised of the CeA, BNST, and the “shell” region of the nucleus accumbens. In a 
position to receive information from limbic structures like the hippocampus and greater 
amygdala, the extended amygdala seems perfectly situated to integrate stress regions 
with hedonic processing systems to produce negative emotional states associated with 
discontinued drug use. Also prevalent in withdrawal states are multiple neurochemical 
systems that may mediate aversive drug states. For example, CRH activates the HPA 
axis after chronic (Koob, 2008), but not acute drug use. Our laboratory and others have 
suggested that PACAP may be upstream of CRH in several stress-related regions and 
may modulate CRH, and subsequent HPA axis activation (see below). In addition to 
CRH, norepinephrine has been shown to be critical to the stress response associated 
with drug withdrawal, as antagonists administered to extended amygdala areas block 
drug-induced place aversion (see Hand et al., 1988; Delfs et al., 2000). 
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Craving Stage: While “craving” has often been suggested as a reason for relapse in the 
clinical realm, the term itself is difficult to define. Some view ‘craving’ as an intense 
desire or longing (Kozlowski & Wilkinson, 1987), while others think of craving as a 
hypothetical construct that can be neither directly observed nor directly measured 
(Peers, 2016). Indeed, craving seems to be a rather subjective state in humans that is 
associated with drug dependence. However, animal models of craving, and subsequent 
relapse, are often studied in the laboratory, as discussed in detail below. Here, cue- and 
stress-induced relapse lend some insight to the neuroanatomical and neurochemical 
mechanisms that may underlie craving and relapse processes. McFarland & Kalivas 
(2001) suggested that drug-induced reinstatement is localized to the nucleus accumbens 
and ventral pallidum and mediated by glutamate, whereas renewal processes (i.e. 
returned drug seeking in the presence of a contextual cue) may be mediated by the 
amygdala (Koob & Volkow, 2016; Everitt & Wolf, 2002; Weiss et al., 2001). Finally, 
stress-induced reinstatement may occur during a period of craving and appears to 
depend on CRH, PACAP, and norepinephrine in the BNST and amygdala (Miles et al., 
2017; Shaham et al., 2003; Shalev et al., 2002). Notably, the BNST receives projections 
from the ventral NE bundle, a cluster of neurons originating from the locus coeruleus 
(LC) and lateral tegmental nuclei. Projections from the lateral tegmental nuclei 
specifically target the BNST, CeA, hypothalamus, and septum (Aston-Jones, et al., 
1999; Aston-Jones et al., 1997; Delfs et al., 1998) and are activated most prominently 
by stressor exposure. The NE bundle, which projects to the BNST and CeA, has been 
implicated in the stress responses associated with CRH activation (Delfs et al., 1998). 
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Both extrahypothalamic sub-structures contain dense populations of CRH-
immunoreactive cells (Shaham, Erb & Stewart, 2000). Furthermore, stressors have been 
shown to increase CRH mRNA in CeA (Hammack et al., 2009; Keifer et al., 2015). 
The role of the BNST (and not the amygdala) is further supported by prior studies of 
CRH administration in the BNST and CeA of animals allowed to lever press for 
cocaine (Erb & Stewart, 1999), suggesting the BNST is a critical structure mediating 
the effects of stress-induced reinstatement after drug self-administration.  
 
1.3. BNST in Addiction Processes 
 
The BNST is a limbic structure of the extended amygdala that has been widely 
implicated in mediating behavioral responses to anxiety and stressor exposure (Choi et 
al., 2008; Walker et al., 2003). In particular, the BNST has been specifically implicated 
in mediating many PACAP-related stress effects (Hammack et al., 2009; 2010; Lezak et 
al., 2014; Roman et al., 2014; Ressler et al., 2011; Vaudry et al., 2002; Stroth et al., 
2011). Anatomically, the BNST is located ventral to the septum, expands both above and 
below the anterior commissure, and is anterior to the hypothalamus (Dong et al., 2001); it 
is often divided into anterior and posterior regions by fibers of the stria terminalis (Ju & 
Swanson, 1989). The anterior region of the BNST can be further divided into well-
accepted sub-nuclei including the anterolateral, anteromedial, oval, dorsomedial, and 
magnocellular regions (Dong et al., 2001), among others. The posterior, in contrast, is 
sub-divided into only three sub-nuclei: the principal, transverse, and interfascicular. Both 
anterior and posterior regions of the BNST have distinct efferent and afferent 
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projections to other regions within the BNST, and to surrounding brain structures. While 
sub-regions of the BNST may differentially regulate stress responding, the anterolateral 
division has been largely connected to the behavioral consequences of stressor exposure 
(Choi et al., 2007). 
 
The BNST receives and integrates information from many limbic regions, including the 
amygdala, prefrontal cortex, and hippocampus. However, the oval nucleus in particular 
may be critical in the integration of mood and negative valance leading to heightened 
anxiety-like behavioral responding. Indeed, CRH, GABA and PACAP all project from 
the oval nucleus to regions further implicated in stress responding, such as the CeA, 
VTA, and hypothalamus (Dong et al, 2001). The VTA has also been implicated in reward 
and motivation, and BNST projections to the VTA appear to regulate dopaminergic cells 
(Georges & Aston-Jones, 2002), further suggesting that the BNST may help integrate 
information from stress and reward pathways.  
 
Optogenetic and electrophysiological manipulations of BNST neural circuits 
Functional circuit mapping of the BNST is essential for elucidating the distinct 
neurocircuitry involved in stress-related behavioral responding. Notably, a study by Kim 
et al. (2013) investigated the neural circuits involved in stress- and anxiety-related 
behaviors as they relate to reward processes. Photoinhibition of BNST elevated open-arm 
time on the EPM (demonstrating increased anxiety), whereas photostimulation of 
channelrhodopsin (ChR2) channels in the BNST led to heightened anxiety. Similarly, 
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photostimulation of BLA-BNST pathways induced decrements in anxiety, while 
inhibition induced heightened anxiety. Furthermore, Jennings et al. (2013) used single-
unit recordings to demonstrate that glutamatergic VTA-projecting neurons increase firing 
during aversive events, while GABAergic VTA-projecting BNST neurons suppress 
firing. Using optogenetic and electrophysiological techniques, Paré and colleagues 
showed that the BNST-CeA projecting neurons that target different BNST sub-nuclei 
exert inhibitory control over prolonged fear (Gungor et al., 2015; Duvarci et al., 2009). 
Lastly, Rainnie et al. (2017) demonstrated that opposing circuits within the BNST 
differentially affect cell types related to anxiogenic or anxiolytic behavioral responses. 
Indeed, electrophysiological studies show that Type III neurons (characterized by 
activation of inwardly rectifying potassium currents; see Hammack et al., 2007) modulate 
BNST circuitry related to CRH neuronal activation, a system specifically relevant to 
chronic stressor exposure. Continued research in this new area offers a potential route 
toward in vivo treatment of stress-related behavioral disorders. 
 
Norepinephrine and Drug Abuse 
 
The noradrenergic system is activated by both acute and chronic stress (for review, see 
Morilak et al., 2005; Koob, 1999; Bangasser et al., 2016). Norepinephrine is also active 
in response to acute withdrawal states and has been widely cited in relation to addiction 
processes (Sinha, 2001; 2007; Blaine & Sinha, 2017; España et al., 2016). Historically, a 
central argument discussing whether NE or dopamine is the key mediator of brain reward 
states has dominated the literature. However, the relationship between 
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psychostimulant self-administration and NE has been widely understood and accepted. 
Norepinephrine was first implicated in reinstatement paradigms in the mid-1970s when 
Davis and colleagues (1975) discovered that blocking NE synthesis attenuates 
reinstatement of amphetamines. Since then, accumulating evidence has shown NE 
systems to have key role in stress-induced reinstatement. Indeed, administration of NE 
receptor (α2AR) agonists decreased NE release by activating inhibitory autoreceptors and 
prevented stress-induced reinstatement (Erb et al., 2000). Furthermore, infusion of an 
α2AR antagonist, yohimbine, facilitates reinstatement (Lee et al., 2004). Importantly, 
these effects seem to involve extended amygdala stress-related areas, as βAR antagonist 
blocked stress-induced reinstatement to cocaine seeking when administered to the BNST 
or CeA (Leri et al., 2002). Additionally, stress-induced reinstatement of morphine 
appears to be NE-dependent: intra-BNST infusion of α2AR agonist, clonidine, blocked 
stress-induced reinstatement in a conditioned place paradigm (Wang et al., 2001). The 
known role of NE in stress responses could point to the extended amygdala as a critical 
component of stress-induced reinstatement. However, the role of BNST CRH and 
norepinephrine in processes related to addiction is complex and may depend on the drug 
investigated.  
 
Norepinephrine originates from several clusters of neurons - the locus coeruleus and the 
lateral tegmental nuclei (NTS) – to project to multiple brain areas via the dorsal and 
ventral noradrenergic bundles (Kvetnansky et al., 2009). Notably, CeA is a major source 
of CRH afferents to the LC that modulates noradrenergic activity, and NE afferent 
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projections directly innervate CRH-containing CeA neurons (Kravets et al., 2015). 
Indeed, the lateral bundle provides extended amygdala regions with norepinephrine 
critical for stress-induced reinstatement of drug seeking. Shaham et al. (2000) showed 
that lesions to this area decreased footshock-induced reinstatement and conditioned place 
preference. Furthermore, reinstatement has been induced (and subsequently diminished 
by CRH receptor antagonist D-Phe CRH) by ventricular infusions of norepinephrine 
(Brown et al., 2009). Hence, CRH is likely downstream from stress-activated 
norepinephrine and integration may occur in the BNST.  
 
The BNST in negative reinforcement processes 
 
Addictive behaviors may be maintained through a system of negative reinforcement (see 
Koob & Volkow, 2010; 2016). Indeed, an escape from anxiety and dysphoria common 
during drug withdrawal may lead to continued drug use. The BNST plays an important 
role in the withdrawal stage of addiction (Silberman et al., 2013; Wang et al., 2006), 
although it has also been shown to be involved in anxiogenic effects of cocaine self-
administration (Su et al., 2014), and enhanced startle responses throughout intoxication 
and craving phases (Logrip et al., 2011). In humans, only a small amount of studies have 
investigated the role of BNST in addiction-related processes. However, rodent studies 
increasingly show that both anxiety- and addiction-related processes may be mediated by 
therapeutic drugs that target the BNST (Walker et al., 2009; Su et al., 2014; Glangetas et 
al., 2013).  
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Anxiety-like Responses in Drug Abuse 
 
Several lines of research have identified a between-system response to acute withdrawal 
from drugs of abuse: anxiety-like responses become prevalent in rodent models of 
cocaine withdrawal, such that open arm time in an elevated plus maze decreases 
(indicative of anxiety-like behavior), a finding that has been reversed by CRH antagonists 
(Koob & Volkow, 2016). This effect, and others, is seen across drugs, and can often be 
reversed by administration of a CRH antagonist (Koob, 2008; Funk et al., 2006; Tucci et 
al., 2003; George et al., 2007). Importantly, these anxiety-like responses may also be 
associated with a decrease in dopaminergic activity in areas associated with the stress 
response, such as regions within the extended amygdala. 
 
Corticotropin Releasing Hormone (CRH) 
 
As mentioned above, CRH appears to be a critical regulator of stress responses, as 
administration of CRH produces the same physiological and behavioral effects as stressor 
exposure. In a clinical setting, patients exhibiting symptoms of major depressive disorder 
(MDD), PTSD, and suicidal thoughts (Ressler et al., 2011; Arato et al., 1989; Baker et 
al., 1999; Nemeroff et al., 1991) have higher levels of CRH in their system than healthy 
counterparts. Depressed individuals also have heightened levels of CRH mRNA in 
extended amygdala areas (Merali et al., 2006). Using animal models, Dunn & colleagues 
have done numerous studies showing that central CRH administration produces 
physiological effects associated with stressor exposure: increased heart rate (Dunn & 
Berridge, 1987), increased anhedonia and anorexic-like behaviors (Dunn & File, 
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1987), low sex drive (Dunn & Berridge, 1990), and reduced social interaction (Dunn & 
File, 1987).  
 
Two CRH receptors mediate CRH activity: CRH-R1 and CRH-R2. As CRH-R1 
antagonists can block the effects of stressor exposure, it is thought that stress effects are 
mediated by CRH-R1 (Binder & Nemeroff, 2010). In support of this, CRH-R1 knockout 
mice exhibit decreased anxiety-like behavior (Timpl et al., 1998), implicating an 
important role of CRH receptors in stress- and anxiety-like behaviors. In the clinical 
realm, it is interesting to note that CRH antagonists have been developed to treat stress-
related illnesses, but have been widely unsuccessful (Zorrilla & Koob, 2010). Hence, 
CRH receptor activation may be sufficient but not critical for stress responses. 
 
Many studies have investigated the neural circuits underlying stress-induced 
reinstatement (Kalivas & Volkow, 2016). For example, Erb & Stewart (1999) have 
implicated activation of CRH in stress-induced relapse. Additionally, Shaham & 
colleagues (1997) demonstrated that an acute intracerebroventricular (ICV) injection of 
CRH mimicked stressor exposure and caused reinstatement, whereas the ICV injection of 
a CRH antagonist, α-helical CRH, blocked stress-induced reinstatement in heroin-trained 
rats. Furthermore, in a follow-up study done in cocaine-trained rats, Shaham et al. (1998) 
showed that CRH receptor antagonists (D-Phe CRH and CP-154.526, respectively) also 
attenuated reinstatement to drug seeking. When tested in drug-primed animals, these 
manipulations had no effect, indicating an important role of CRH specifically in the 
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stress-induced reinstatement paradigm. Initially, the sites of this CRH action were 
unclear; however, subsequent studies implicated the BNST as a critical site for stress-
induced reinstatement of drug- seeking behavior.  
 
1.4. Pituitary Adenylate Cyclase Activating Peptide (PACAP) 
 
First identified from ovine hypothalamus because of its ability to stimulate cyclic 
adenosine monophosphate (cAMP; Miyata et al., 1989) production in pituitary cells, 
PACAP has since been implicated in many other areas, including brain, vascular tissues, 
and endocrine and immune responses. Indeed, PACAP has been implicated as a key 
regulator of signaling in stress-related brain regions (Hammack & May, 2015; Stroth et 
al., 2011). A neurotrophic factor, PACAP promotes cell survival of multiple neuron 
types, including progenitor cells, dorsal root ganglion cells, cerebellar granule cells, and 
peripheral sympathetic neurons (Stroth et al., 2011). Importantly, PACAP has been 
shown to increase cell survival in response to stressor exposure (Stroth et al., 2013). The 
peptide belongs to the vasoactive intestinal peptide (VIP) – secretin – growth-hormone 
releasing hormone (GHRH) – glycagon family and shares multiple characteristics with 
peptide VIP (68% amino acid homology; Miyata et al., 1989, 1990). PACAP cDNA 
contains codes for a 176-amino-acid protein, which is cleaved into either a 38-amino-acid 
or 27-amino-acid form; PACAP38 predominates over PACAP27 in the nervous system 
(Vaudry et al., 2009). PACAP-ergic fibers innervate multiple stress-related regions, and 
large populations of these fibers are found in the hypothalamus, amygdala, and BNST. 
Indeed, the highly conserved nature of PACAP suggests that it may play a critical 
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role in survival. This is supported by the activation of both the HPA axis and the SNS by 
systemic and environmental stressors: researchers have postulated that PACAP regulates 
stress hormone synthesis in a chronic-stress paradigm (Stroth et al., 2011). PACAP binds 
to multiple receptor subtypes: PAC1 (exclusively binds PACAP), VPAC1, and VPAC2 
(both of which bind PACAP and VIP; for reference, see May et al., 2010). By binding to 
these receptors, PACAP can have various effects on intracellular mechanisms (such as 
membrane depolarization and neurotransmitter release; see Figure 1.5 & discussion of 
signaling pathways below; Harmar et al., 2012), including neurotrophic and 
neurotransmitter-like effects. Furthermore, alternative splicing of the PAC1 receptor 
allows even greater signaling diversity: short and long N-terminal extracellular regions 
result in differing isoforms that can affect the ability of PAC1 to bind to specific ligands. 
Splicing variations can also affect the presence of base-pair cassettes “hip” and “hop,” 
further varying the ability of ligand-binding specificity.  
 
PACAP & PAC1 receptors in emotional behaviors 
 
Our laboratory and others have argued that PACAP plays a crucial role in stress 
responding (for review, see Hammack et al., 2009; 2010; Lezak et al., 2014; Mustafa et 
al., 2015; Missig et al., 2014). Hence, PACAP may also play an important role in 
addiction processes. Indeed, addiction, or substance abuse, is itself a chronic stressor, and 
as noted above, many addiction processes may be regulated by stressor exposure. PACAP 
and PAC1 receptors are highly expressed in areas that project to the HPA axis, and 
several studies have demonstrated the importance of PACAP in HPA signaling 
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(Stroth et al., 2011). Furthermore, Stroth and colleagues (2011) demonstrated an increase 
in CRH transcription in response to PACAP in hypothalamic cells, and ICV 
administration of PACAP increased CRH mRNA in the PVN (Hashimoto et al., 2011). 
Finally, PACAP null mice have exhibited impaired long-term HPA axis activation in 
response to chronic stressors, an idea that supports the importance of PACAPs role in 
HPA axis regulation during a stressful situation (Vaudry et al., 2005; Hammack et al., 
2010). Interestingly, mice deficient in PACAP, when exposed to ethanol, demonstrated 
higher tendency to seek the substance than control mice (Tanaka et al., 2010).  
 
Our laboratory has demonstrated that an intra-BNST infusion of PACAP mimics 
behavioral and physiological responses to stressor exposure (see Hammack et al., 2009; 
2010; Miles et al., 2017). For example, when exposed to a seven-day chronic variate 
stress paradigm, rats exhibit anxiety- and anorexic-like behaviors that correspond with a 
significant increase in PACAP and PAC1 receptors in the BNST. Bilateral intra-BNST 
infusion of PACAP on its own was sufficient to cause the same stress-related behaviors, 
including anorexic- and anxiety-like behaviors (Kocho-Schellenberg et al., 2014; Lezak 
et al., 2014; Roman et al., 2014). Indeed, PACAP infusions can mimic chronic stress-
related responses by increasing startle, anxiety-like behavior on the elevated plus maze 
(i.e. rodents spend more time in the closed arm, indicative of anxiety), decreasing weight 
gain and feeding behaviors, and elevating circulating corticosterone levels (Hammack et 
al., 2009; Roman et al., 2014; Kocho-Schellenberg et al., 2014; Lezak et al., 2014; King 
et al., 2017). Additionally, the bilateral intra-BNST infusion of a PAC1 receptor 
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antagonist reduced the stress-induced consequences of repeated variate stress, suggesting 
that PACAP in the BNST is necessary for the stress responses observed (Roman et al., 
2014). Combined, these data implicate PACAP as an important regulator of stress-related 
pathologies (Hammack et al., 2012). Finally, there is some evidence linking PACAP to 
different disease states: in humans, PACAP and PAC1 levels are associated with PTSD 
and other stress-related disorders in women (Ressler et al., 2011; Hashimoto et al., 2011; 
Hashimoto et al., 2016), further implicating PACAP/PAC1 in stress- and anxiety-related 
states. 
 
In many stress-related regions, PACAP-immunoreactive fibers appear more prevalent 
than soma, suggesting that PACAP signaling may be involved in long-distance 
projections (Hammack et al., 2010) rather than local circuits. Furthermore, the source of 
PACAP is still largely unknown: originally isolated from the pituitary gland, the highest 
densities of PACAP are in the PVN and brainstem regions (Kozicz et al., 1998). 
Recently, researchers have demonstrated that PACAP-immunoreactive fibers synapse in 
close proximity to CRH-expressing neurons in the PVN and BNST (Sherwood et al., 
2000; Roman et al., 2014; Missig et al., 2014). Hence, PACAP may regulate 
neuroendocrine and behavioral responses to stressor exposure via CRH-dependent 
mechanisms. That is, PACAP may be upstream of CRH activation. Indeed, 
intracerebroventricular (ICV) administration of PACAP has been shown to increase CRH 
mRNA in the PVN and CeA (Dore et al., 2013). Hence, stress-released PACAP may bind 
to PAC1 receptors on CRH neurons, inducing the synthesis of CRH and eventually 
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leading to increased corticosterone levels (although increased plasma corticosterone 
levels itself does not necessarily require CRH receptor activation; Meloni et al., 2016; 
Lezak et al., 2014; Norrholm et al., 2005). This idea is further supported by studies done 
with PACAP knockout mice: here, corticosterone release is diminished in response to 
chronic stressor exposure (Stroth & Eiden, 2010), open field exposure (Tsukiyama et al., 
2011) and social defeat stress (Lehmann et al., 2013), but not physical stressors like cold 
exposure. Additionally, Roman et al. (2014) showed that PACAP receptor antagonism 
via BNST PACAP6-38 administration during a chronic variate stress paradigm reduces 
corticosterone release. (While the PACAP6-38 antagonist has been used in multiple 
behavioral pharmacology studies in our lab and others, it blocks both the PAC1 and 
VPAC2 receptors, so direct effects of PAC1 activity are unknown). Finally, ICV 
administration of PACAP reduces sensitivity to reward in sucrose preference and 
intracranial self-stimulation (ICSS) tasks (Dore et al., 2013; Seiglie et al., 2015), both 
effects that are blocked by CRH antagonists. Hence, PACAP signaling may mediate the 
activation of the HPA axis in ways both associated to and disconnected from CRH 
receptor activation.  
 
PACAP & PAC1 receptors in addiction-releated behaviors 
 
Recent experiments (Miles et al., 2017) were designed to examine the relationship 
between PACAP38, a polypeptide that has been shown to drive BNST CRH, and its 
receptor antagonist, PACAP6-38, in stress-induced reinstatement to drug-seeking. We 
found that an infusion of PACAP into the BNST was sufficient to reinstate 
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previously-extinguished cocaine seeking behavior (Figure 1.1). Furthermore, infusion of 
PAC1 receptor antagonist, PACAP6-38, immediately before stressor exposure, attenuated 
reinstatement to drug seeking when paired with a stressor (Figure 1.2). In an experiment 
designed to determine whether 10 days of cocaine self-administration training elevated 
BNST PACAP transcripts, similar to what we have previously reported with chronic 
stressor exposure (Hammack et al., 2009), we found a five-fold increase in PACAP 
mRNA transcript levels in the dorsal aspect of the anteriolateral BNST (dBNST) in 
cocaine-responding animals compared to cocaine non-responding animals (Figure 1.3). 
Importantly, this increase in PACAP expression appears to be a result of chronic (10d) 
cocaine self-administration, as acute cocaine expression (1d) did not alter PACAP 
expression compared with control (Figure 1.4). There were no changes in PAC1 or 
VPAC2 receptor expression in the same samples, and no difference in transcript levels 
following extinction training, indicating that BNST PACAP transcripts likely return to 
control level after extinction of the cocaine-seeking behavior (Figure 1.3). Additionally, 
while Miles et al. (2017) showed that 10 days of cocaine self-administration significantly 
elevated BNST PACAP transcript levels, PAC1, CRH, VIP, VPAC1, and VPAC2 
transcript levels, when analyzed, were unchanged. BNST PACAP transcript levels were 
not elevated by the reinstatement footshock treatment; however, it is possible that 
footshock may lead to peptide release that is not reflected in changes in mRNA. Our 
laboratory has previously demonstrated a change in both PACAP transcript and PACAP 
immunostaining in the dorsal aspect of the anterolateral BNST following chronic stress, 
but changes in protein following chronic cocaine exposure remain unknown. 
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Consistent with a role for active PACAP during reinstatement testing, infusion of 
PAC1/VPAC2 receptor antagonist, PACAP6-38, immediately before footshock exposure 
prevented the footshock from reinstating extinguished cocaine seeking, thus suggesting 
that BNST PAC1/VPAC2 receptor activation is necessary for stress-induced 
reinstatement of the response. These dissertation experiments (discussed in detail below) 
were designed to examine whether this activation is, indeed, necessary. 
 
PAC1 signaling through extracellular signaling related kinase (ERK) activation 
 
As mentioned above, the mechanism of action underlying PACAP signaling can occur 
through three G-protein coupled receptors: PAC1, VPAC1 or VPAC2. Activation of 
these receptors has been shown to initiate signaling cascades that can phosphorylate 
extracellular signal-related kinase (ERK) proteins that go on to influence multiple 
intracellular events (see Figure 1.5; Chang & Karin, 2001). Given the complexity of the 
intracellular signaling pathways downstream of PAC1 receptor activation, it is possible 
that several signaling pathways lead to pERK activation. Our lab and others have shown 
that pERK activation requires endosomal signaling in CeA (May et al., 2010; May & 
Parsons, 2017; Missig et al., 2017). Indeed, pretreatment of a PAC1 receptor cell line 
with PACAP6-38 (antagonist) blocked PAC1-EGFP receptor internalization typically 
stimulated by PACAP. ERK activation here was also diminished, implicating endogenous 
CeA PAC1 endosomal ERK signaling in a nociception pathway. Behaviorally, Missig et 
al. (2017) showed that a reduction in thermal latency to CeA-infused PACAP 
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could be prevented if tested after administration of MEK inhibitor PD98059 or clathrin-
dependent endocytosis inhibitor Pitstop2. That is, inhibition of clathrin-mediated 
endocytosis by Pitstop2 reduced PACAP-induced hypersensitivity on Hargreaves test, 
suggesting that PAC1 receptor internalization and subsequent downstream ERK signaling 
can modulate nociception responses in the CeA. It is possible that the same signaling 
pathways mediate the reinstatement of cocaine seeking behavior following BNST 
PACAP (or maxadilan) infusion, or footshock stress. In this set of experiments, we tested 
the ability of clathrin-mediated endocytosis inhibitor Pitstop2 to prevent footshock-
induced reinstatement following cocaine self-administration and extinction. 
 
Recent work in a model of chronic neuropathic pain demonstrated that PACAP and 
phosphorylated ERK (pERK) immunoreactivity was preferentially heightened in the CeA 
following a chronic constriction injury (CCI; Missig et al., 2017). In this paradigm, ERK 
activation may be a central means of nociceptive signaling, and MEK inhibition to 
attenuate CeA PACAP-stimulated pERK in the presence of a blockade of PACAP-
induced behavioral tests demonstrated that PACAP/PAC1 receptor mediated ERK 
signaling is a requisite for CeA nociceptive hypersensitivity responses in a CCI model 
(Missig et al., 2017). In addition, CCI induced a robust increase in anterolateral BNST 
pERK cells that were in close proximity to glutamatergic PACAP fibers (Missig et al., 
2017). Furthermore, activation of the ERK transcriptional pathway leads to cocaine-
induced behavioral plasticity (Girault et al., 2007), and acute cocaine is known to 
increase pERK levels within mouse striatum and NAcc (Janes et al., 2009), while a 
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challenge dose increases pERK in rats that had previously experienced cocaine (Yoon et 
al., 2007). Hence, pERK may be sensitized prior to this cocaine re-exposure. In this set of 
experiments, we sought to identify specific signaling events that likely mediated 
PACAP/PAC1-induced increases in BNST pERK, and subsequent relapse, during a 
stress-induced reinstatement paradigm. Missig et al. (2017) demonstrated that PACAP38 
infusion into the CeA, similar in both structure and function to the BNST, increased 
pERK expression. This expression was diminished by the presence of clathrin-mediated 
endocytosis inhibitor, Pitstop2, and mitogen-activated protein kinase enzyme 
(MEK)/ERK inhibitor, PD98059. To establish whether BNST PACAP signaling via ERK 
can evoke stress-induced reinstatement, the two inhibitors were utilized in this set of 
experiments to determine whether their presence abolished footshock/PAC1-stimulated 
response to suggest that ERK activation is a critical component of PACAP/PAC1 
receptor signaling. Finally, we sought to determine the prevalence of pERK cells 
immediately after a stress-induced reinstatement paradigm in which rats receive either 
footshock or no-footshock paired with an intra-BNST infusion of PACAP6-38 or vehicle 
solution. If pERK expression is mediated by PAC1, the presence of an intra-BNST 
antagonist (PACAP6-38) during stressor exposure (i.e. footshock) should prevent the 
presence of pERK in an immunohistochemistry analysis. In contrast, animals who receive 
the vehicle solution paired with a footshock after cocaine exposure should have “normal” 
levels of pERK following stressor exposure, as PACAP-bound PAC1 receptors should 
facilitate an intracellular cascade responsible for pERK expression.  
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1.5 Summary 
 
Central to the treatment of drug addiction is understanding the cellular mechanisms by 
which relapse episodes occur. Prior and current data suggest the activation of BNST 
PACAP systems is an important event underlying stress-induced reinstatement to drug 
seeking in rodents. Hence, these dissertation experiments aimed to clarify the intra-
cellular mechanisms by which PAC1 receptor activation by PACAP mediates stress-
induced reinstatement. The results of these studies are presented in manuscript form in 
the following chapters. 
 
While stressor exposure has been linked to human relapse, neuronal mechanisms that 
underlie these events are largely unclear. In the laboratory, we have seen the BNST as a 
key regulator of reinstatement to drug seeking behavior and suggest that the release of 
PACAP in this region mediates changes in emotional responding following stressor 
exposure. A growing literature has discussed PACAPs important role in the modulation 
of stress and anxiety. The present studies were designed to help further the understanding 
of PACAPs role in stress-induced reinstatement. Data from these experiments will help 
elucidate PACAPs role in activation of the HPA axis and how stressor exposure triggers 
relapse behaviors after a period of abstinence.  
 
These experiments expand upon recent research I conducted examining PACAPs role in 
stress-induced reinstatement to drug-seeking behavior (Miles et al., 2017) and, together, 
may point to the BNST as an important target in the treatment of drug relapse. Continued 
 29 
research of mechanisms that underlie stress-induced reinstatement after a period of 
abstinence may lead to the development of viable treatments for relapse prevention. 
However, a better understanding of the intracellular mechanisms involved in relapse 
processes will be critical to determine how best to target returned drug-seeking. 
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1.6 Figures 
 
Figure 1.1. Intra-BNST PACAP38 causes reinstatement of extinguished cocaine 
seeking. (A) Self-administration training. Animals in both the PACAP38 and Vehicle 
groups received the same amount of cocaine during acquisition (inset). (B) Extinction 
training. Extinction sessions occurred during the 20 days after self-administration 
training. (C) PACAP38 infusion causes significant reinstatement on the active lever 
during test for reinstatement compared with the last day of extinction (1 day before test).  
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Figure 1.2. Intra-BNST PACAP antagonist (PACAP6-38) attenuates stress-induced 
reinstatement in rats.  
(A) Self-administration training. Animals in both the footshock/no-footshock and 
vehicle/antagonist groups received the same amount of cocaine during acquisition (inset). 
(B) Extinction training. (C) To determine whether PACAP receptor activation during 
footshock is necessary for stress-induced reinstatement of cocaine-seeking behavior, we 
infused the PAC1/VPAC2 receptor antagonist PACAP6-38 into the BNST during the test 
phase of the stress-induced reinstatement procedure. Intra-BNST PACAP6-38 attenuates 
stress-induced reinstatement when delivered before intermittent footshock. Intra-BNST 
delivery of the PACAP antagonist significantly attenuated shock-induced reinstatement. 
Only animals that received intra-BNST vehicle treatment before footshock demonstrated 
reinstatement of extinguished drug-seeking behavior.  
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Figure 1.3. Cocaine self-administration alters endogenous PACAP levels in the 
BNST. Adult male rats self-administered cocaine for 10d, and several underwent 20d 
extinction training. dBNST was harvested for quantitative PCR analysis after 10d self-
administration, or after self-administration followed by 20d extinction training. (C) 10d 
cocaine self-administration increases PACAP in cocaine responders, but not non-
responders. Neither 10d cocaine self-administration nor 20d extinction training altered 
(D) PAC1 or (E) VPAC2 receptor transcript in cocaine responders and non-responders in 
the BNST. 
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Figure 1.4. PACAP transcript levels after acute cocaine self-administration. Acute 
cocaine exposure (1d) did not alter PACAP expression compared to control. 
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Figure 1.5. Modified schematic of PAC1 receptor signaling cascade. Arrestin 
molecules aid in endosome signaling following PAC1 receptor internalization. They then 
serve as scaffolds for adaptor proteins and enzymes for extracellular signal-related kinase 
(ERK) pathway activation. MEK pathways may also interact with ERK signaling. 
Clathrin dependent endocytosis inhibitor (Pitstop2) will serve to inhibit endosomal 
signaling. Thus, PAC1-mediated stress-induced reinstatement may be altered. MEK 
inhibitor PD98059 serves to block MEK, further downstream of PAC1. Blocking this 
stage of the cell signaling cascade prevents stress-induced reinstatement to drug-seeking 
in the presence of footshock.  
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CHAPTER 2: INTRA-BNST MAXADILAN INFUSION MIMICS STRESSOR 
EXPOSURE AND INDUCES REINSTATEMENT OF DRUG-SEEKING 
BEHAVIOR 
 
2.1. Introduction 
 
The BNST PACAP receptor subtypes mediating the reinstatement of cocaine-seeking 
behavior by stress are unknown. Therefore, Experiment 1 was designed to specifically 
test whether PAC1 (rather than VPAC1 or VPAC2) receptor activation mediates stress-
induced reinstatement. As mentioned above, our laboratory has produced data 
demonstrating that an intra-BNST infusion of PACAP38 (Figure 1.1) mimics stressor 
exposure and induces reinstatement to drug-seeking following a period of extinction in 
rats who learned to lever-press for cocaine. Furthermore, infusion of PAC1/VPAC2 
receptor antagonist, PACAP6-38, immediately before footshock exposure prevented the 
footshock from reinstating extinguished cocaine seeking (Figure 1.2), suggesting that 
BNST PAC1/VPAC2 receptor activation is necessary for stress-induced reinstatement of 
the response. These results are consistent with hypotheses suggesting that stress systems 
have a role in the vulnerability to relapse following stressor exposure (Koob & Le Moal, 
2008). Hence, BNST PACAP activation may be critical for regulating extinguished drug 
seeking following stressor exposure. 
 
PACAP effects can be mediated by three receptor subtypes that bind with different 
affinities to PACAP and VIP. PAC1 receptor activation can lead to the 
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activation of several intracellular signaling cascades, including adenylate cyclase (AC) 
and phospholipase C (PLC), depending on the PAC1 receptor isoform activated. The 
resulting activation can subsequently result in heightened membrane depolarization, 
neurotransmitter release, and action potential firing (Harmer et al., 2012; Spongier et al., 
1993; Braas & May, 1999). Also activated are pathways important for neurodevelopment 
and neuroplasticity following stressor exposure, such as the ERK and phosphoinositide 3-
kinase (PI-3) pathways. Furthermore, PACAP/PAC1 dysregulation may participate in the 
development of physiological disorders, such as anxiety and depression (Hammack & 
May, 2015).  
 
Our laboratory has previously reported that chronic stress (but not cocaine self-
administration; Experiment 1 in Miles et al., 2017) upregulates BNST PAC1 receptor 
transcripts, but not BNST VPAC1/VPAC2 transcripts (Lezak et al., 2014; Hammack et 
al., 2009). Moreover, many of the consequences of stressor exposure can be mimicked by 
infusion of the PAC1 receptor agonist maxadilan in the BNST (Roman et al., 2014). 
Indeed, PACAP-induced anxiety-like and anorexic responses have been fully 
recapitulated with an infusion of maxadilan. A 61-amino acid sand fly salivary gland 
peptide, maxadilan is currently the only PAC1 receptor specific ligand identified to date 
and demonstrates high efficacy in initiating behavioral responses that match those 
produced by PACAP- or stress-induced states. Hence, it is likely that the stress-like 
effects of BNST PACAP activation are mediated by PAC1 receptors.  
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From these observations, we hypothesized that maxadilan treatment would recapitulate 
our previous findings (Experiment 3 in Miles et al., 2017) and mimic stress-induced 
reinstatement. Here, we utilized a stress-induced reinstatement paradigm in which 
animals were allowed to lever-press for cocaine for 10 days, followed by 20 days 
extinction training (where lever presses no longer resulted in drug delivery) and a test day 
where animals received vehicle or maxadilan treatment paired with either footshock or no 
footshock. Since we propose the PAC1 receptor is responsible for PACAP- and stress-
mediated reinstatement, we expected to see an increase in active lever (previously 
associated with cocaine delivery) responses on test day for animals who received intra-
BNST maxadilan and previously learned the cocaine lever-press association compared to 
animals who received vehicle treatment. 
 
2.2. Materials & Methods 
 
Subjects 
Consistent with our work investigating the role of BNST PACAP in stress-related 
behavior, adult male Sprague-Dawley rats (n=30) obtained from Charles River 
Laboratories (Canada), were individually housed and received water and chow ad 
libitum. After delivery, rats were allowed to habituate to their home cage for 1 week 
before undergoing surgeries. Rats were maintained on a 12h light/dark cycle (lights on at 
0700 h) and all experimentation occurred with lights on (between 0730 and 1130). All 
procedures were approved by the institutional animal care and use committee at the 
University of Vermont.  
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Apparatus 
Two sets of four conditioning chambers were used. Each is housed in its own sound-
attenuation chamber (Model ENV-008-VP; Med Associates; St. Albans, VT). The 
chambers measure 30.5 x 24.1 x 21.0 cm (length x width x height). The floor is made of 
stainless steel grids (0.48 cm diameter). The sidewalls and ceilings are made of clear 
acrylic plastic, whereas the front and rear walls are made of brushed aluminum. A 
retractable lever (4.8 cm long and positioned 6.3 cm above the grid floor) is positioned on 
the right and left sides of the chamber (the left-hand lever was used as a control (inactive) 
lever). A stimulus light is positioned above each lever, and each chamber is illuminated 
by a 7.5 incandescent bulb mounted to the ceiling of the sound-attenuation chamber, ~35 
cm from the grid floor at the front of the chamber. The operant conditioning chambers are 
linked to a computer data collection program (MED PC, Med Associates).  
 
Surgical Procedures 
All rats received a jugular vein catheter implantation. Rats were anesthetized using 
isoflurane vapor (1.5-4.0%) and all surgical procedures were conducted using aseptic 
techniques. Catheters were constructed using methods previously described (Fuchs et al., 
2004) and consisted of external guide cannula with screw-type connectors (Plastics One, 
Roanoke, VA), silastic tubing (10 cm; SAI Infusion Technology, Lake Villa, IL), and 
prolite polypropylene monofilament mesh (2 cm diameter; Biomedical Structures, 
Warwick, RI). The end of the catheter was inserted into the right jugular vein, secured 
with suture, and exited on the rat’s back, posterior to the shoulder blades. To maintain 
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patency, catheters were flushed once daily for 6 days after surgery with 0.2 ml 
heparinized saline. For the duration of the experiment, each animal received 0.1 ml 
heparinized saline immediately before and directly after each self-administration session 
to ensure catheter patency.  
 
Immediately following the jugular catheterization, animals were implanted with bilateral 
cannula (22 gauge, Plastics One, Roanoke, VA) aimed at the BNST as previously 
described (Hammack et al., 2009). Cannula were mounted onto stereotaxic arms and 
aimed at an angle of 20° just dorsal to the oval BNST (from bregma: AP = -0.1, ML = 
+3.8, DV = -5.3). Wire stylettes extending 1 mm past the tip were inserted into each 
guide cannula and cemented in place. Animals received subcutaneous injections of 
lactated Ringer’s solution and an analgesic (5mg/kg, Metacam, Boehringer Ingelheim, 
Vetmedica, St. Joseph, MO) administered once immediately after the dual surgery and 
once the following day. Once awake, rats were returned to their home cages for 7-day 
post-surgery recovery, during which all rats were observed and weighed daily.  
 
Cocaine Self-Administration (Acquisition) 
At 7 days after surgery, all rats were given the opportunity to self-administer cocaine 
(cocaine hydrochloride, 3.0mg/ml, obtained from PENRO Specialty Compounding, 
Colchester, VT) during daily 1 hr sessions for 10 days according to a fixed ratio 1 
schedule of reinforcement. At the start of each session, the catheter was connected to a 
swivel via polyethylene 20 tubing that was encased in steel spring lashes (Plastics One). 
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After the animals were placed in the chamber, a 2 minute period elapsed before the 
stimulus light came on above the active lever (signaling drug availability). Presses on the 
active lever resulted in a 0.5s cocaine infusion and a 2s flashing light presentation of the 
stimulus light above the active lever (0.5s on/0.5s off).  
 
Extinction 
Over the next 20 days, all rats received a single daily session in which levers were 
available but had no programmed consequence (i.e. lever presses no longer resulted in 
cocaine delivery). These extinction sessions lasted 1 hr. 
 
Reinstatement 
On the day following the last extinction session, rats were split into four groups, 
counterbalanced for order and time of testing, that received different treatments. Rats 
received an infusion into the BNST of PAC1 specific agonist maxadilan (1.0 µg; 0.5 
µl/side; gifted from Ethan Lerner, Harvard/Massachusetts General Hospital) to 
recapitulate previous findings and confirm the involvement of the PAC1 receptor, or 
equivolume 0.05% BSA saline vehicle immediately before the test session (between 0730 
and 0930 h) as previously described (Hammack et al., 2009). For all infusions, rats were 
lightly restrained with a cloth towel and the stylettes removed and replaced with an 
internal cannula, extended 1 mm distally, for infusions at 0.25 µl/minute. Following 
infusion, the internal cannula was left in place for 1 minute to allow complete diffusion of 
the drug away from the infusion tip. Immediately following bilateral infusion, the rats 
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were placed in the operant conditioning chambers and allowed to lever press for 1 hr.  
 
Histology 
Rats were anesthetized 1 day after reinstatement testing with Beuthanasia-D (sodium 
pentobarbital; Zoestis, Kalamazoo, MI) solution and perfused transcardially with 200 ml 
saline (0.9%) with 0.1% heparine (Sagent, Schaumburg, IL) followed by 100ml of 10% 
formalin solution (Fisher Scientific, Atlanta, GA). Brain tissues were postfixed at 4°C for 
24 h in 10% formalin. Fixed tissue was then cut using a cryostat, and sections were 
collected at 60 µm thickness. Sections were then dry mounted, stained with cresyl violet 
stain, and cover slipped. Cannula placements were visualized using a 4x Nikon Objective 
on an Olympus microscope. Only data from correct BNST cannulae placements are 
described in the Results.  
 
Data Analysis 
Statistical analysis was completed using SPSS Version 21 software (IBM Software, 
Armonk, NY) and graphical representations were completed using GraphPad Version 6 
(GraphPad Software, San Diego, CA). 
 
2.3. Results 
 
Our previous studies (Miles et al., 2017) have implicated the PAC1 receptor in stress-
induced reinstatement to drug-seeking: an intra-BNST infusion of PACAP38 (Figure 1.1) 
mimics stressor exposure and induces reinstatement to drug-seeking following a 
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period of extinction. PACAP binds to several PACAP/VIP receptor subtypes, as 
discussed above, and prior studies have implicated BNST PAC1 receptor signaling in 
stress-related responses (Roman et al., 2014). Infusion of maxadilan, the only PAC1 
receptor-specific ligand identified to date, was expected to mimic stressor exposure and 
induce reinstatement of active lever press responding in the absence of stressor exposure. 
 
Figure 2.1 illustrates the timeline of Experiment 1. Data from 22 animals were used in the 
analyses for the tests for reinstatement, as post-test histological examination of injection 
sites for these rats were found to be placed appropriately in the BNST. Three animals 
who completed behavioral testing had improperly placed cannula and were excluded 
from the analysis; two animals lost skull caps during infusion and were immediately 
sacrificed prior to behavioral test; three animals lost skull caps during extinction training 
and were not included in any analyses. Figure 2.2 portrays the distribution of cannula 
placements in analyzed animals. 
 
Self-Administration Training 
Immediately after the last acquisition session, a median split analysis for total lever 
presses over 10d was used to separate cocaine responders (M=172, SD=13.3; those who 
successfully learned the lever press response and progressively increased responding over 
acquisition) from cocaine non-responders (M=35, SD=3.47; those who did not learn the 
lever press behavior and received very little drug over acquisition). Cocaine responders 
self-administered an average [mean (±SEM)] of 17.2 (± 0.79) infusions of cocaine HCL 
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per hour, 0.75mg/kg/infusion, over the 10 days of acquisition; cocaine non-responders 
self-administered an average of 3.5 (± 1.02) infusions per hour, 0.75mg/kg/infusion, over 
the same 10 d period. The mean (±SEM) number of responses made on the inactive lever 
throughout acquisition was uniformly low across responders and non-responders per 
session, 1.59 (± 0.68). Furthermore, there was a significant time effect in cocaine 
responders (F(1,8)=14.39, p<0.01), but not cocaine non-responders (F(1,8)=1.42, N.S.) 
over acquisition, indicating that only cocaine responders learned the lever press response 
and increased responding over time. Data is portrayed in Figure 2.3 (A).   
 
Extinction 
By the end of extinction (Figure 2.3 (B)), all cocaine responders had reached ≤ 10 
responses; cocaine non-responders reached ≤ 5 responses. Inactive lever responses 
remained uniformly low throughout extinction. Interestingly, in this experiment (more so 
than Experiments 2, 3, & 4; see below), extinction responses between cocaine responders 
and non-responders remained significantly different throughout the 20 days of training. 
Figure 2.3 (B) shows a distinct difference in active lever responding on the last day of 
extinction for cocaine responders vs. non-responders, perhaps indicative of the 
reinforcing effects of cocaine administration during acquisition such that cocaine 
responders continued to lever press slightly throughout extinction in the hopes of 
receiving an infusion. There was a significant effect of time in cocaine responders 
(F(1,8)=7.94, p<0.05), but not non-responders, indicating that lever press responses on 
the active lever significantly decreased over extinction. The mean (±SEM) number of 
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responses made on the active and inactive levers on the last day of extinction and during 
the test for reinstatement are shown in Figure. 2.3 (C, D). 
 
Reinstatement 
Bilateral intra-BNST infusion of selective PAC1 receptor agonist, maxadilan, 
significantly increased active lever responding in the test session in cocaine responders. 
Only rats that received maxadilan increased responding on the active lever during the test 
for reinstatement. No significant differences in responding were found between animals 
infused with BSA vehicle solution. A treatment (maxadilan, vehicle) by session (last day 
of extinction, test) ANOVA supported these observations. There was a significant effect 
of session (F(1,8)=8.042, p<0.05), and a session by treatment interaction (F(1,8)=7.332, 
p<0.05). Importantly, animals in both the maxadilan and vehicle groups received the 
same amount of cocaine during acquisition (Figure 2.4), indicating that reinstatement was 
elicited by maxadilan infusion rather than total cocaine intake during acquisition. The 
post hoc analyses comparing maxadilan and vehicle infusion on total responses on the 
active lever in the absence of footshock stress revealed significantly more responding in 
the maxadilan condition. Maxadilan did not alter responding on the inactive lever, and 
responses on the inactive lever remained uniformly low during testing.  
  
In contrast, maxadilan infusion had no effect on active lever responses on test day in 
cocaine non-responders (F(1,8)=0.4298, NS). Hence, maxadilan infusion only increases 
active lever press responding (and mimics stress-induced reinstatement) if the animal is 
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cocaine experienced, a finding that may be PACAP dependent. This data, and other 
experiments in this dissertation, may suggest a permanent change in the PACAP system 
(i.e. sensitization) following cocaine exposure.  
   
2.4. Discussion 
 
To facilitate understanding of PACAPs role in the BNST, our prior studies (Miles et al., 
2017) demonstrated that PACAP infusions into the BNST mimicked stress-induced 
reinstatement behavioral responses. The effects of PACAP are mediated by both PAC1 
and VPAC2 receptors. Here, we showed that stress- and PACAP-elicited BNST 
behavioral effects could be recapitulated using maxadilan, implicating specific activation 
of the PAC1 receptor in these behavioral responses. Maxadilan was first isolated from the 
salivary gland of the sand fly in 1991 and has been widely studied as a vasodilator 
peptide (Tatsuno et al., 2001; Lerner et al., 2007). While maxadilan appears biologically 
active and has effects at specific binding sites, the peptide itself is not endogenous to 
mammals. However, as noted above, maxadilan does bind to PACAP receptors in 
mammals despite its lack of amino acid homology with PACAP. Indeed, Moro and 
colleagues (1999) showed that maxadilan binds specifically to the PAC1 receptor, as 
deletion of 17 amino acids from maxadilan (max.d.4) resulted in a peptide with binding 
affinity for PAC1, but no functional activity. The mutated max.d.4 failed to activate 
downstream targets of the PAC1 receptor (and was eventually deemed a competitive 
antagonist of PAC1 receptors), demonstrating that maxadilan specifically interacts with 
PAC1 to stimulate downstream cyclic AMP production. Furthermore, maxadilan, but 
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not VIP, increases the excitability of guinea pig cardiac neurons (Braas et al., 1998; 
Hoover et al., 2009). 
 
Prior studies (Miles et al., 2017) demonstrated an increase in PACAP transcript following 
10d cocaine self-administration, but no increase in PAC1 transcript. Perhaps the 
increased PACAP transcripts represent a decrease in PACAP binding to PAC1 receptors 
due to heightened PAC1 receptor internalization: if mature PACAP is prevented from 
binding due to PAC1 receptor internalization, but available in the synapse, mRNA 
transcripts may not undergo translation to make more peptide (discussed below; May et 
al., 2014; Merriam et al., 2013; May & Parsons, 2017). That is, as PAC1 receptors 
undergo clathrin-mediated endocytosis, they are no longer available to bind PACAP, 
which would explain our finding that PACAP transcript levels are increased following 
cocaine self-administration, but PAC1 transcript levels remain unchanged. These studies 
in aggregate implicate PACAP and PAC1 receptor involvement in the behavioral 
consequences of stress-induced reinstatement to drug-seeking.  
 
Within the BNST, the location of PAC1 receptors mediating stress-induced reinstatement 
is unknown. However, prior studies have revealed a cluster of CRH neurons within the 
dorsolateral and ventrolateral regions of the BNST with higher concentrations in the oval 
nucleus (Silberman et al., 2013) that appear to mediate many effects of drug-related 
anxiety and reinstatement (Jennings et al., 2013). Indeed, Erb and colleagues (2001) 
suggested a prominent role of CRH projections from the CeA in stress-induced 
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reinstatement. But more recent studies have shown that stress activates neurons in the LC 
that release norepinephrine and elicit action potentials from CRH neurons within the 
BNST (Silberman et al., 2013). Since CRH neurons in the BNST are primarily 
GABAergic, actions on these neurons may be involved in anxiety-inducing aspects. 
Perhaps PAC1 receptors on CRH neurons within the BNST are responsible for cocaine 
“withdrawal” during extinction and subsequent reinstatement to drug-seeking following 
stressor exposure. 
 
VIP, a neuropeptide with strong homology with PACAP, has similar biological functions 
to PACAP within the central nervous system (CNS). PACAP and VIP both form the 
PACAP/VIP receptor family to which PACAP and VIP both bind with different 
affinities. Several studies have suggested that VIP may mimic the physiological action of 
PACAP but requires large concentrations to show biological effects (Pincus et al., 1990). 
In vivo, PACAP could be acting in conjunction with VIP to stimulate receptors 
responsible for the behavioral reactions to stressor exposure. Here, if animals had not 
reinstated drug-seeking on test day in response to maxadilan infusion, it would have been 
feasible that previously reported results depend on the VPAC2 receptor, which also binds 
PACAP. However, Miles et al. (2017) showed that chronic cocaine administration did not 
alter VIP, VPAC1 or VPAC2 transcript levels in the BNST. This makes logical sense, as 
the BNST contains high expression of PAC1 receptors (Kash et al., 2015; Hashimoto et 
al., 1996) and little expression of VPAC1 and VPAC2 receptors (Ishihara et al., 1992; 
Kash et al., 2015). Hence, PAC1 is the most likely post-synaptic target of BNST PACAP.  
 48 
 
Recently, Ressler and colleagues (Ressler et al., 2011; Dias & Ressler, 2013) showed that 
traumatized women had higher levels of blood PACAP than healthy age-matched 
controls, which complements studies showing an increase in PACAP and PAC1 mRNA 
transcripts in the extended amygdala of adult rodents following a fear conditioning 
paradigm. Together, these findings suggest that PACAP may be involved in some of the 
symptoms characteristic of women with post-traumatic stress disorder (PTSD; Dias & 
Ressler, 2013). Because the PACAP-PAC1 receptor system has been studied for its role 
in stress responsiveness (Hammack et al., 2009; Vaudry et al., 2009; Stroth et al., 2011), 
the possible convergence between stress and biological components of PTSD should be 
further investigated. Furthermore, stressor exposure has been shown to induce relapse in 
vulnerable former addicts. Hence, there may be concordance between stressor exposure 
(i.e. trauma), drug-use, and subsequent stress-induced relapse that depends on the 
extended amygdala PACAP system.  
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2.5 Figures 
 
 
 
 
 
Figure 2.1. Timeline for Experiment 1.  
Jugular catheterizations and BNST cannulations were performed concurrently in rats for 
self-administration and test-day infusions, as shown in the experimental timeline. This 
was followed by one week of post-operative recovery, 10d cocaine self-administration 
training, 20d extinction training, and a test day. Infusions of maxadilan or vehicle 
treatment occurred 15 minutes prior to the animals’ reintroduction to the operant 
conditioning chambers on test day. Animals were perfused 1d after test for cannula 
verification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cocaine SA (10 days) Post-Op (7 days) Extinction (20 days) 
Test for Reinstatement 
Jugular Catheterization & BNST 
Cannulation Surgeries 
Intra-BNST Infusion of Maxadilan or 
Vehicle 15 min prior to behavioral test 
Perfusion 
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Figure 2.2. BNST Cannula Placements. 
Cannula placements are depicted above such that enclosed red dots represent a 1mm 
extension beyond the tip of the cannula. Rats were included in the analysis if their 
placement resided within a portion of the BNST; they were eliminated from analysis if 
their cannulae placement fell outside the histological boundary of the BNST, fell within 
the lateral ventricles, or if animals did not complete behavioral testing. 
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Figure 2.3. Intra-BNST maxadilan infusion induces reinstatement of drug-seeking 
in the absence of stressor exposure. 
(A) Self-administration training on the active lever during Experiment 1; inactive lever 
presses remained uniformly low throughout acquisition. A median split analysis for total 
lever presses over 10d was used to separate cocaine responders (M=172, SD=28.89) from 
non-responders (M=35, SD=3.47). (B) Extinction training during Experiment 1. 
Extinction sessions occurred during the 20 days after self-administration training. (C) To 
determine whether PAC1 receptor activation is necessary during reinstatement to drug-
seeking, we infused the PAC1 specific receptor agonist maxadilan into the BNST 
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during the test phase of the reinstatement procedure. Intra-BNST maxadilan induces 
reinstatement on the active lever (previously associated with cocaine delivery) in cocaine 
responders, but not cocaine non-responders (D) in the absence of footshock stress. Only 
animals that received intra-BNST maxadilan treatment demonstrated reinstatement of 
extinguished drug-seeking behavior. Group Responders-Vehicle, n=6; Responders-
Maxadilan, n=6 Non-Responders-Vehicle, n=5; Non-Responders-Maxadilan, n=5. Data 
represent mean lever presses ± SEM. 
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Figure 2.4. Total cocaine infusions over 10d acquisition. 
Animals in both the maxadilan (M=175.5 SD=38.12) and vehicle (M=159.8, SD=58.36) 
groups received the same amount of cocaine during acquisition, indicating that 
reinstatement was elicited by maxadilan infusion rather than total cocaine intake during 
acquisition.  
 
 
 
 
 
 
 
 
 
 54 
 
CHAPTER 3: COCAINE EXPERIENCE POTENTIATES SHOCK-INDUCED 
pERK VIA PAC1 RECEPTOR MECHANISM 
 
3.1. Introduction 
 
Our laboratory has previously reported that PAC1 receptor activation leads to 
intracellular signaling cascades that result in increased pERK expression. Furthermore, 
Experiment 1 was designed to determine whether PAC1 receptor activation could 
recapitulate the effects of stress on cocaine reinstatement. Theoretically, with the 
exposure of a stressor (i.e. footshock), PACAP release should bind to the PAC1 receptor 
and activate intracellular signaling cascades that, in addition to opening different ion 
channels, increases pERK expression. Furthermore, it is well known that cocaine 
activates stress response systems in addition to reward systems. Hence, it is feasible that 
cocaine self-administration alone activates the PAC1 signaling cascade and subsequently 
increases pERK expression.  
 
The pharmacology of PACAP in the BNST is complex, but Walker et al. (2014) recently 
showed that both splice variants of PACAP (38 vs. 27), but not VIP, activate cellular 
cAMP production. Furthermore, in an experiment examining the effects of PACAP 
protection against high-alcohol and high-nicotine toxicity, Manavalan and colleagues 
(2017) showed that PACAP blocks toxicity induced by high alcohol and nicotine, but 
these effects of PACAP were blocked after PACAP6-38 administration. Our 
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laboratory has previously demonstrated a change in both PACAP transcript and PACAP 
immunostaining in the dorsal aspect of the anterolateral BNST following chronic stress 
(Hammack et al., 2009). Consistent with a role for active PACAP during reinstatement 
testing, infusion of PAC1/VPAC2 receptor antagonist, PACAP6-38, immediately before 
footshock exposure prevented the footshock from reinstating extinguished cocaine 
seeking, thus suggesting that BNST PAC1/VPAC2 receptor activation is necessary for 
stress-induced reinstatement of the response (Miles et al., 2017). Here, we proposed that 
stressor exposure during a test for reinstatement induces ERK phosphorylation and, 
therefore, increases pERK levels in the BNST. Our prior results are consistent with 
hypotheses suggesting that stress systems have a role in the vulnerability to relapse 
following stressor exposure (Koob & Le Moal, 2008), and prior work has suggested that 
BNST PACAP activation may be critical for regulating extinguished drug seeking 
following stressor exposure.  
 
3.2. Materials & Methods 
 
Subjects, Apparatus, & Surgical Procedures 
The subjects were 26 naïve male Sprague Dawley rats of the same age and from the same 
vendor as those in Experiments 1. They were also maintained under the same conditions 
and utilized the same apparatus as that used in Experiment 1. All animals received both 
the jugular catheterization and BNST cannulation as described above.  
 
Cocaine Self-Administration (Acquisition) 
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Seven days post-surgery, animals were allowed to lever press for cocaine (cocaine 
hydrochloride, 3.0mg/ml, obtained from the same vendor as in Experiment 1) during 
daily 1 h sessions for 10 days according to a fixed ratio schedule of reinforcement. 
Animals received the same conditions inside the operant chambers as animals in 
Experiment 1. 
 
Extinction 
Extinction sessions proceeded as described in Experiment 1. 
 
Reinstatement 
On the day following the last day of extinction, rats were split into four groups, 
counterbalanced for order and time of testing, that received different treatments. Rats 
received an infusion into the BNST of the PAC1 receptor antagonist PACAP6-38 (1µg) 
paired with footshock or no footshock to observe downstream pERK activation, or 
equivolume 0.05% BSA saline vehicle immediately before test. Directly following 
bilateral infusion, animals were placed into the operant conditioning chambers and 
allowed to lever press (while active and inactive lever presses were recorded; no cocaine 
was delivered to the animals during test day). Animals were broken into groups based on 
three factors: Cocaine responders vs. non-responders, Footshock vs. No Footshock, and 
Antagonist vs. Vehicle treatment. Hence, the groups were as follows: Responders-Shock-
PACAP6-38, n=4; Responders-NoShock-PACAP6-38, n=4; Responders-Shock-Vehicle, 
n=4; Responders-NoShock-Vehicle, n=4; NonResponders-Shock-PACAP6-38, n=3; 
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NonResponders-NoShock-PACAP6-38, n=3; NonResponders-Shock-Vehicle, n=2; 
NonResponders-NoShock-Vehicle, n=2.  
 
Histological and Immunohistochemistry Procedures 
One hour after the test session ended, rats were deeply anesthetized with Beuthanasia-D 
(sodium pentobarbital; Zoestis, Kalamazoo, MI) solution and perfused transcardially with 
saline, followed by a 4% paraformaldehyde solution before tissue dissection. All tissues 
were post-fixed overnight in 4% paraformaldehyde, rinsed in phosphate buffer saline, and 
equilibrated in 30% sucrose before cryosections (30 µm) were floated in PBS for 
staining. All sections were then permeabilized with 0.3% Titron X-100 and blocked with 
1% BSA. Immunocytochemical staining for pERK (1:1000, Phospho-p44/42 MAPK 
(Erk1/2) Rabbit monoclonal antibody, #4370 Cell Signaling Technology, Danvers, MA) 
occurred after extensive buffer rinses, and was followed by treatment with a species-
specifi AlexaFluor 488 secondary antibody (1:500, 4hr; ab150077; Abcam). 
 
Image Analysis 
Micrographs were acquired with a 10x objective using an Olympus fluorescence 
microscope (Nikon Instruments, Melville, NY) and StereoInvestigator (MBF 
Biosciences, Williston, VT) software. BNST fields in the different brains were identified 
using the anterior commissure, lateral ventricles, and outer field of the caudate putament 
as reference points and landmarks. All images for this experiment were acquired under 
identical settings and parameters. For enumeration of pERK cells in prescribed areas, a 
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semi-autonomous cell counting method was utilized. All data represents mean values ± 
SEM. 
 
Data Analysis 
All statistical tests were performed as described in previous experiments. 
 
3.3. Results 
 
Figure 3.1 displays the timeline of events for Experiment 2. Data from 26 animals were 
used in the analysis for the tests for reinstatement, as histological examination of 
injection sites for these rats were found to be placed appropriately in the BNST. Figure 
3.2 portrays the distribution of cannula placements in analyzed animals.  
 
Self-Administration Training 
The results of acquisition, extinction, and testing are shown in Figure 3.3. As in 
Experiment 1, a median split analysis for total lever presses over the 10d of acquisition 
was used to separate cocaine responders (M=95.14, SD=2.98), from non-responders 
(M=37, SD=0.68). Both groups performed uniformly low on the inactive lever. Cocaine 
responders self-administered an average of 9.5 (±0.94) infusions of cocaine HCL per 
hour, 0.75mg/kg/infusion, over the 10 days of acquisition; cocaine non-responders self-
administered an average of 3.7 (±0.21) infusions per hour, 0.75mg/kg/infusion, over the 
same 10d period. The mean number of responses made on the inactive lever throughout 
acquisition was uniformly low across responders and non-responders per 
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session, 1.24 (±0.24). 
 
Extinction 
By the end of extinction, all rats had reached ≤ 5 responses; inactive lever responses 
remained uniformly low throughout extinction. The mean number of responses made on 
the active and inactive levers on the last day of extinction and during the test for 
reinstatement are show in Figure 3.3 (C, D). 
 
Reinstatement 
Bilateral intra-BNST infusion of PAC1 receptor antagonist PACAP6-38 significantly 
attenuated active lever responding in the test session of cocaine responders after stressor 
exposure. Only animals that received vehicle solution paired with footshock increased 
responding on the active lever during test for reinstatement (stress-induced reinstatement 
that has been well documented by our laboratory and others). No significant differences 
in responding were found between animals infused with BSA vehicle solution. A 
treatment (PACAP6-38, vehicle) by session (last day of extinction, test) ANOVA 
supported these observations. In cocaine responders, there was a significant effect of 
session (F(1,9)=80.37, p<0.0001), and significant interactions between session and shock 
(F(1,9)=2.616, p<0.05), and session and infusion treatment (F(1,9)=7.11, p<0.01). 
Finally, there was a significant session by shock by infusion treatment interaction 
(F(1,9)=5.50), p<0.01), consistent with the fact that only animals that received the 
footshock and vehicle infusion demonstrated stress-induced reinstatement. Cocaine 
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responders in both vehicle and antagonist group received the same amount of cocaine 
during acquisition (Figure 3.4), indicating that reinstatement was elicited by footshock 
exposure rather than total cocaine intake during acquisition. Hence, these results 
completely recapitulate previous findings that demonstrate PACAP6-38 blocks 
reinstatement of extinguished cocaine seeking when exposed to footshock stress (see 
Miles et al., 2017, Experiment 2). The post hoc analysis comparing PACAP6-38 and 
vehicle infusion on total responses on the active lever after footshock exposure revealed 
significantly less responding in the PACAP6-38 condition (p<0.01). Additionally, the 
number of responses on the active lever in the no-footshock condition after injections of 
PACAP6-38 did not differ from lever press activity after vehicle infusion. PACAP6-38 
did not alter responding on the inactive lever, and responses remained uniformly low 
during testing. 
 
There was no significant difference in any condition (footshock vs. no footshock; 
PACAP6-38 vs. vehicle) in cocaine non-responders on test day compared to the last day 
of extinction. Hence, PACAP6-38 appears only to block stress-induced reinstatement if 
the animal is cocaine experienced.  
 
BNST ERK Signaling in Stress-Induced Reinstatement 
This experiment sought to completely block the PAC1 receptor (using PAC1 antagonist 
PACAP6-38, as described above) and observe subsequent pERK levels in the presence 
and absence of stress. Pretreatment with PACAP6-38 prior to footshock significantly 
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lessened pERK expression in cocaine responders (compare Figure 3.5 (A, C, I)). In 
cocaine responders, compared to no-fooshock (Figure 3.5 (B, D, I)), footshock exposure 
increased the number of activated phosphorylated ERK neurons (Figure 3.5 (A, I)), but 
pretreatment with PACAP6-38 blocked the ability of footshock stress to induce ERK 
phosphorylation in BNST neurons (Figure 3.5 (C, I)). The increase in footshock-
stimulated ERK activation was attenuated approximately 60-70% by PACAP6-38 
(vehicle + footshock = 88.58 ± 12.45 cells vs. PACAP6-38 + footshock = 33.9 ± 9.50 
cells, [bonferroni’s m.c. t(13)=3.92, p<0.05]). There was a significant interaction between 
pre-treatment (vehicle vs. PACAP6-38) by stress (footshock vs. no footshock), 
F(2,13)=2.43, p<0.05. While there was no difference between pERK expression in 
cocaine responders who received no-footshock (vehicle + no footshock = 33.75 ± 7.23 
cells; PACAP6-38 + no-footshock = 32.44 ± 4.89 cells), there was a significant 
difference in pERK expression in cocaine responders regardless of infusion or stress 
treatment compared to cocaine non-responders: cocaine non-responders had very little 
pERK expression in the BNST (group means ±SEM: vehicle + footshock = 17.5 ± 5.63; 
PACAP6-38 + footshock = 3.25 ±0.83; vehicle + no-footshock = 5.75 ±1.49; PACAP6-
38 = 9.0 ± 3.24). Hence, footshock only increases pERK if the animal is cocaine 
experienced, a finding that may be PACAP dependent. This data suggests a permanent 
change in the PACAP system following cocaine exposure. 
 
There was very little pERK expression overall in cocaine non-responders (see Figure 3.5 
(E-H, J), such that no significant differences were found between groups who received 
 62 
vehicle or PACAP6-38 infusion or footshock vs. no-footshock. Hence, most shock-
induced pERK signaling appears to be PACAP dependent, especially when the animal is 
cocaine experienced.   
 
3.4. Discussion 
 
In Experiment 1, we showed that BNST PAC1 receptor activation is necessary for stress-
induced reinstatement, as selective PAC1 receptor agonist maxadilan infusion caused 
drug-seeking on test day in the absence of stress. Here, we show that shock-induced 
pERK signaling is dependent on PACAP receptor activation, especially in cocaine 
responders. Endogenous BNST PACAP/PAC1 signaling is relevant in mediating stress- 
and anxiety-induced behaviors. Hence, PAC1/VPAC2 receptor antagonism via 
administration of PACAP6-38 should block related behaviors. Following a week-long 
chronic variate stress paradigm, Roman et al. (2014) showed that PACAP6-38 infusions 
blunted stress-induced anxiety-like responses on an elevated plus maze (EPM), blocked 
anorexic-like effects, and significantly decreased stress-induced corticosterone release (a 
hormone typically released in response to stress). These results suggest that PACAP is 
released during footshock in cocaine experienced rats, and this release and/or its response 
is potentiated by cocaine self-administration. 
 
Blockade of PAC1/VPAC2 by PACAP6-38 also has noticeable effects outside the BNST: 
in spinal cord neurons, blockade attenuates neuropathic and inflammatory pain (Davis-
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Taber et al., 2008); in the BLA, PACAP6-38 blocks fear conditioning (Schmidt et al., 
2015); and intra-CeA blockade attenuates chronic-pain induced behavioral responses 
(Missig et al., 2017). In the current experiment, we did see that intra-BNST infusion of 
PACAP6-38 attenuated stress-induced reinstatement (replicating our prior work; Miles et 
al., 2017), and reduced pERK expression after footshock exposure if the animals were 
cocaine-experienced (i.e. cocaine responders). That is, when PAC1/VPAC2 receptors are 
blocked, stressor exposure is no longer sufficient to reinstate drug-seeking behavior. 
However, intra-BNST infusion of PACAP6-38 into cocaine non-responders had no effect 
on stress-related reinstatement behaviors or pERK expression, suggesting that 
endogenous PACAP signaling in animals who are not cocaine experienced may be too 
low to impact BNST functions. Additionally, lack of reinstatement and noticeable 
decrease of pERK expression may imply that BNST PACAP signaling modulates the 
reinstatement of drug-seeking in animals who consistently lever pressed for cocaine but 
does not affect pERK expression under normal conditions (i.e. if the animal is not drug 
experienced). The ability of PACAP6-38 to lessen stress-induced reinstatement after a 
period of chronic (10d) self-administration and extinction (20d) suggests that BNST 
PACAP levels increase and remain elevated throughout the 30 total days of behavior to 
facilitate the stress-induced behavioral responses. 
 
Prior work in our laboratory has led to the hypothesis that drug-use activated PACAP 
systems upstream of CRH in the oval BNST which mediates CRH in the PVN to 
stimulate a stress response. If true, administration of PAC1/VPAC2 antagonist PACAP6-
 64 
38 infusion into the BNST may block receptors responsible for maintaining downstream 
PVN CRH (a necessary component of the stress response). Support for this idea comes 
from studies conducted by Stewart (2000) describing the role of CRH in stress-induced 
reinstatement: CRH receptor antagonist, D-Phe CRH blocks footshock-induced 
reinstatement. The present study (and Miles et al., 2017) suggests that PACAP regulates 
CRH activity in the PVN and, subsequently, behavioral stress responses.  
 
Effects of BNST PAC1 receptor activation are likely mediated by intracellular signaling 
cascades that manifest in increased pERK expression. Multiple PAC1 receptor isoforms 
may be coupled to several distinct intracellular signaling pathways: G-protein coupled 
activation of AC or PLC, or endosomal signaling by the PAC1 receptor itself via 
receptor-arrestin scaffolding proteins. A point of convergence for these multiple 
pathways may be the phosphorylation of ERK (Hammack & May, 2015). The remaining 
two experiments aimed to determine the signaling mechanisms that mediate heightened 
ERK phosphorylation following BNST PAC1 receptor activation in rats who undergo a 
stress-induced reinstatement paradigm.  
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3.5. Figures 
 
 
 
 
 
 
 
 
Figure 3.1. Timeline for Experiment 2. Jugular catheterizations and BNST cannulations 
were performed concurrently in rats for self-administration and test-day infusions, as 
shown in the experimental timeline. This was followed by one week of post-operative 
recovery, 10d cocaine self-administration training, 20d extinction training, and a test day. 
Infusions of PACAP6-38 or vehicle treatment occurred 15 minutes prior to the animals’ 
reintroduction to the operant conditioning chambers on test day. During test, animals 
received either footshock or no-footshock. Animals were perfused 30m after the end of 
their behavioral test for tissue harvest and subsequent immunohistochemistry procedures. 
 
Cocaine SA (10 days) Post-Op (7 days) Extinction (20 days) 
Test for footshock-induced 
reinstatement 
Jugular Catheterization & 
BNST Cannulation 
Surgeries 
Intra-BNST Infusion of PACAP6-38 or 
Vehicle 15 min prior to behavioral test 
Perfusion, 30 
min after test 
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Figure 3.2. BNST Cannula Placements. 
Cannula placements are depicted above such that enclosed red dots represent a 1mm 
extension beyond the tip of the cannula. Rats were included in the analysis if their 
placement resided within a portion of the BNST; they were eliminated from analysis if 
their cannulae placement fell outside the histological boundary of the BNST, fell within 
the lateral ventricles, or if animals did not complete behavioral testing. 
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Figure 3.3. Intra-BNST infusion of PACAP6-38 attenuates stress-induced 
reinstatement. 
(A) Self-administration training on the active lever during Experiment 4; inactive lever 
presses remained uniformly low throughout acquisition. A median split analysis for total 
lever presses over 10d was used to separate cocaine responders (M=95.14, SD=2.98) 
from non-responders (M=37, SD=0.68). (B) Extinction training during Experiment 4. 
Extinction sessions occurred during the 20 days after self-administration training. (C) To 
determine whether PAC1 receptor activation is necessary during reinstatement to drug-
seeking, we infused PAC1 receptor antagonist PACAP6-38 or vehicle into the BNST 
paired with footshock or no footshock during the test phase of the reinstatement 
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procedure. Stressor exposure only caused reinstatement to extinguished drug-seeking in 
cocaine responders who received intra-BNST vehicle solution; PACAP6-38 pre-
treatment completely attenuated drug-seeking behavior following stressor exposure. (D) 
There were no differences between the last day of extinction and test day in cocaine non-
responders, and no effect of vehicle vs. PACAP6-38 infusion. Group n’s are as follows: 
cocaine responders-noshock-vehicle, n=4; cocaine responders-noshock-PACAP6-38, 
n=4; cocaine responders-shock-vehicle, n=4; cocaine responders-shock-PACAP6-38, 
n=4; cocaine non-responders-noshock-vehicle, n=2; cocaine non-responders-noshock-
PACAP6-38, n=3; cocaine non-responders-shock-vehicle, n=2; cocaine non-responders-
shock-PACAP6-38, n=3. Data represent mean lever presses ± SEM. 
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Figure 3.4. Total cocaine infusions over 10d acquisition. 
Animals in groups Vehicle/Footshock (M=52.0, SD=5.91), Vehicle/NoFootshock 
(M=62.6, SD=5.92), PACAP6-38/Footshock (M=47.6, SD=7.35), and PACAP6-
38/NoFootshock (M=48.6, SD=9.32) received the same amount of cocaine during 
acquisition, indicating that reinstatement was elicited by footshock stress rather than total 
cocaine intake during acquisition. 
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Figure 3.5. PAC1 receptor activation and ERK activation participate in BNST-
mediated reinstatement to drug-seeking. 
Compared to no-stress (B, I), footshock stress increased the number of activated 
phosphorylated ERK neurons in cocaine responders (A, I). Pretreatment with PAC1 
antagonist, PACAP6-38, blocked the ability of footshock to induce ERK phosphorylation 
(C, I). Cocaine non-responders had uniformly low levels of pERK expression regardless 
of shock or infusion treatment (E, F, G, H, J). Scale bar: 100 µm. Data represent mean 
cell number ±SEM. 
 
I J 
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CHAPTER 4: BLOCKADE OF CLATHRIN MEDIATED ENDOCYTOSIS BY 
PITSTOP2 ATTENUATES STRESS-INDUCED REINSTATEMENT TO 
COCAINE-SEEKING 
 
4.1. Introduction 
 
In Experiment 1 (Chapter 2), we successfully mimicked footshock-induced reinstatement 
using selective PAC1 receptor agonist maxadilan. Furthermore, PAC1 receptor activation 
has been shown to facilitate downstream signaling cascades responsible for stress-
associated behaviors. And, footshock-induced pERK expression following cocaine self-
administration is dependent on PACAP receptor activation. However, PAC1 signaling is 
complex (see Hammack & May, 2015; Figure 1.5), and can promote short- and long-term 
neuronal activity. Notably, PAC1 has been shown to activate intracellular signaling 
cascades that potentiate plasticity in regions like the BNST, perhaps in response to stress 
or drug self-administration. Hence, PAC1 receptor isoforms can differentially couple to 
Gαs and Gαq to initiate adenylate cyclase (AC) or phospholipase C (PLC), both of which 
potentiate ERK signaling. Additionally, the PAC1 receptor may bind to arrestin 
molecules acting as scaffolding for enzymes related to subsequent ERK activation. 
Binding to a β-arrestin complex promotes endosome signaling following internalization 
of the receptor itself (May & Parsons, 2017; Hammack & May, 2015). Indeed, Merriam 
and colleagues (2013) demonstrated PAC1 receptor internalization following PACAP 
treatment at 37°C, in EGFP-PAC1 tagged HEK293 cells; notably, pre-treatment with 
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clathrin-mediated endocytosis inhibitor Pitstop2 blocked this internalization and 
subsequently lessened downstream ERK activation (Merriam et al., 2013). This suggests 
that PAC1 receptor internalization and the effects on downstream ERK pathways 
(following footshock-induced PACAP release) may be critical for stress- and PACAP-
induced effects. 
 
PAC1 receptor internalization as a means of ERK phosphorylation 
As mentioned, there are several potential intracellular routes to ERK activation, but 
recent studies have implicated PAC1 receptor internalization via clathrin-mediated 
endocytosis by β-arrestin proteins as an important mediator of downstream cell signaling. 
Notably, the presence of PACAP in cell culture experiments with HEK PAC1-EGFP 
cells facilitated PAC1 receptor internalization (May et al., 2014; May & Parsons, 2017). 
However, pre-treatment with clathrin-mediated endocytosis inhibitors Pitstop2 or 
dynasore inhibited PAC1 internalization but had no effects on PACAP generation of 
cAMP. 
 
In CeA, Pitstop2 pre-treatment markedly blocked PACAP-mediated c-fos expression and 
ERK phosphorylation (Missig et al., 2017). Furthermore, inhibition of clathrin-mediated 
endocytosis reduced PACAP-induced hypersensitivity in a model of chronic pain 
(chronic constriction injury of the sciatic nerve; CCI), which may suggest that PAC1 
receptor internalization and subsequent ERK activation can modulate nociception. 
Recently, when tested in HEK cells expressing PAC1-type receptors, endocytosis 
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blockers (Pitstop2 and Dynasore) reduced ERK expression in the presence of PACAP 
(May et al., 2014). HEK cells expressing VPAC-type receptors also exhibited diminished 
pERK levels after pretreatment with endocytosis blockers in the presence of PACAP 
(Anne Linden & Victor May, personal communication), suggesting that PACAP actions 
at both VPAC- and PAC1-type receptor activation results in elevated pERK that can be 
eliminated with the addition of an endocytosis blocker (perhaps due to the global nature 
of endocytosis blockers, discussed below).  
 
Chapter 2 demonstrated that selective activation of the PAC1 receptor mimicked stress- 
and PACAP-induced reinstatement, and Chapter 3 showed that shock-induced pERK 
signaling is dependent on PACAP receptor activation. Hence, we hypothesized that 
activation of PAC1 receptors facilitates downstream signaling cascades responsible for 
relapse-associated behaviors. This experiment therefore sought to block a downstream 
target of the PAC1 receptor, specifically the β-arrestin complex partially responsible for 
facilitating PAC1 receptor internalization, in an effort to elucidate the signaling pathway 
involved in stress-induced reinstatement. Importantly, we hoped to determine whether 
endosomal signaling of the PAC1 receptor mediated behavioral consequences of stressor 
exposure to lead to relapse-related actions. Indeed, since PAC1 endocytosis may lead to 
the direct activation of signaling molecules like MEK through the activation of the 
receptor-arrestin complex, this study aimed to specifically inhibit the complex using 
clathrin-mediated endocytosis inhibitor Pitstop2. We suggest that stress-induced 
reinstatement is mediated partially by footshock-induced PAC1/PACAP receptor 
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activation, and blockade of downstream targets of this receptor/peptide binding, such as 
the receptor-arrestin complex, will attenuate stress-induced reinstatement when paired 
with stress. 
 
4.2. Materials & Methods 
 
Subjects, Apparatus & Surgical Procedures 
Thirty naïve male Sprague Dawley rats of the same age and from the same vendors as 
those in Experiment 1 were used in this study. They were maintained under the same 
conditions and utilized the same apparatus as that used in Experiment 1. All animals 
received both the jugular catheterization and BNST cannulation surgeries as described in 
Chapter 2.  
 
Cocaine Self-Administration (Acquisition) 
As in Experiment 1 (Chapter 2), animals were allowed to lever press for cocaine 
hydrochloride (3.0mg/ml, obtained from the same vendor as in Experiment 1) during 
daily 1 h sessions for 10 days according to a fixed ratio schedule of reinforcement. 
Animals received the same conditions inside the operant chamber as animals in 
Experiment 1. 
 
Extinction 
Extinction sessions proceeded as described in Experiment 1. 
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Reinstatement 
On the day following the last day of extinction, rats were split into four groups, 
counterbalanced for order and time of testing, that received different treatments. Rats 
received an infusion into the BNST of clathrin-mediated endocytosis inhibitor Pitstop2 
(30 µM) or equivolume 0.05% BSA saline vehicle paired with footshock (intermittent 5 s 
2mA footshock over 1h; average of 6 shocks per test session per animal) or no footshock 
to observe the effects of inhibition on downstream PAC1 receptor targets.  
 
Directly following bilateral infusion, animals were placed into the operant conditioning 
chambers and allowed to lever press. Active and inactive levers were available, and 
presses recorded, but no drug was available during test day. Animals were broken into 
groups based on three factors: Cocaine Responders vs Non-Responders, Footshock vs. 
No Footshock, and Pitstop2 vs. Vehicle solution. Hence, the groups were as follows: 
Responder-shock-Pitstop2, n=3; Responder-Shock-Vehicle, n=3; Responders-NoShock-
Pitstop2, n=3; Responders-NoShock-Vehicle, n=5; NonResponders-Shock-Pitstop2, n=4; 
NonResponders-Shock-Vehicle, n=3; NonResponders-NoShock-Pitstop2, n=3; and 
NonResponders-NoShock-Vehicle, n=3.  
 
Histological and Immunohistochemistry Procedures 
Thirty minutes after the end of the test session (i.e. 1.5 hours after intra-BNST infusion 
and the start of behavioral testing), animals were anesthetized and perfused transcardially 
with saline followed by 4% paraformaldehyde. Brains were postfixed for 24 h, washed 
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and equilibrated in 30% sucrose before embedding in optimal cutting temperature (OCT) 
compound (ThermoFisher Scientific, Waltham, MA) for cryosectioning (40 µm). All 
sections were mounted onto subbed slides, permabilized with 0.3% Titron X-100, 
blocked with 1% BSA, and incubated in primary antibody (1:1000, Phospho-p44/42 
MAPK (Erk1/2) Rabbit monoclonal antibody, #4370 Cell Signaling Technology, 
Danvers, MA) for visualization of pERK using species specific AlexaFluor 488 (1:500; 
4hr; ab150077; Abcam). 
 
Image Analysis 
Micrographs were obtained using an Olympus fluorescence microscope with identical 
parameters for each image. For quantification of BNST pERK immunoreactivity, the 
corresponding BNST fields in the different brains were identified using the anterior 
commissure, lateral ventricles, and outer field of the caudate putamen as reference points; 
area of threshold was used as an indicator of relative fluorescence from same sized fields. 
For enumeration of BNST pERK in fixed areas, a semi-autonomous cell counting method 
was performed in StereoInvestigator (MBF Biosciences, Williston VT). All data 
represent mean values ± SEM. 
 
Data Analysis 
All statistical tests were performed in SPSS (version 22) and GraphPad PRISM (version 
6). Two-way analysis of variance (ANOVA) was performed to examine main effects and 
interactions, and Bonferroni’s multiple comparison tests were used to compare different 
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groups for all experiments, except where indicated. 
 
4.3. Results 
 
Since PAC1 endocytosis may lead to the direct activation of signaling molecules like 
MEK through the activation of the receptor-arrestin complex, we sought to specifically 
inhibit this complex using clathrin-mediated endocytosis inhibitor Pitstop2. Previous 
studies have implicated endogenous CeA PAC1 receptor endosomal ERK signaling in 
pain pathways, and Pitstop2 pretreatment blocked PACAP-mediated ERK 
phosphorylation. Behaviorally, the inhibition of clathrin-mediated endocytosis by 
Pitstop2 reduced PAC1/PACAP-induced thermal hypersensitivity in Hargreaves test 
(Missig et al., 2017). Hence, we hypothesized that stress-induced reinstatement is 
mediated partially by PAC1/PACAP receptor activation, and blockade of downstream 
targets of this receptor/peptide binding, such as the receptor-arrestin complex, will 
attenuate stress-induced reinstatement when paired with stressor exposure. 
 
Figure 4.1 illustrates the timeline of events for Experiment 3. Data from 27 animals were 
used in the analyses for the tests for reinstatement, as post-test histological examination 
of injection sites for these rats were found to be placed appropriately in the BNST. Two 
animals had improperly placed cannula and were excluded from the analysis; one lost his 
skullcap during infusion and was immediately sacrificed and eliminated from all 
analyses. Figure 4.2 portrays the distribution of cannula placements in analyzed animals. 
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Self-Administration Training 
Immediately after the last acquisition session, a median split analysis for total lever 
presses over 10d was used to separate cocaine responders (M=88.5, SD=6.12) from 
cocaine non-responders (M=25.25, SD=9.14). Cocaine responders self-administered an 
average [mean (±SEM)] of 8.85 (±2.45) infusions of cocaine HCL per hour, 
0.75mg/kg/infusion, over the 10 days of acquisition; cocaine non-responders self-
administered an average of 2.5 (±2.18) infusions per hour, 0.75mg/kg/infusion, over the 
same 10d period. The mean (±SEM) number of responses made on the inactive lever 
throughout acquisition was uniformly low across responders and non-responders per 
session, 1.13 (±0.43) (Figure 3.3 (A)). 
 
Extinction 
By the end of extinction, all rats had reached ≤ 5 responses; inactive lever responses 
remained uniformly low throughout extinction. The mean (±SEM) number of responses 
made on the active and inactive levers on the last day of extinction and during the test for 
reinstatement are shown in Figure 3.3 (B). 
 
Reinstatement 
Bilateral intra-BNST infusion of clathrin-mediated endocytosis inhibitor Pistop2 
significantly attenuated active lever responding in the test session of cocaine responders 
after stressor exposure. Only rats that received vehicle solution paired with footshock 
increased responding on the active lever during test for reinstatement (consistent with 
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prior data). No significant differences in responding were found between animals infused 
with BSA vehicle solution. A treatment (Pitstop2, vehicle) by session (last day of 
extinction, test) ANOVA supported these observations. Regarding cocaine responders, 
there was a significant effect of session (F(1,6)=5.53, p<0.05), and significant 
interactions between session and shock (F(1,6)=12.86, p<0.01), and session and infusion 
treatment (F(1,6)=1.67, p<0.05). Finally, there was a significant session by shock by 
infusion treatment interaction (F(1,6)=13.12, p<0.01), consistent with the fact that only 
animals that received the footshock and vehicle infusion demonstrated stress-induced 
reinstatement. Notably, cocaine responders in both the vehicle and Pitstop2 group 
received the same amount of cocaine during acquisition (Figure 3.4), indicating that 
reinstatement was elicited by footshock exposure rather than total cocaine intake during 
acquisition. Pitstop2 blocked reinstatement of extinguished cocaine seeking when rats 
were exposure to a shock stressor. The post hoc analyses comparing Pitstop2 and vehicle 
infusion on total responses on the active lever after footshock exposure revealed 
significantly less responding in the Pitstop2 condition (p<0.01).  Additionally, the 
number of responses on the active lever in the no-footshock condition after injections of 
Pitstop2 did not differ from lever press activity after vehicle infusion. Pitstop2 did not 
alter responding on the inactive lever (F(1,6)=3.40, NS) and responses remained low 
during testing. 
 
Regarding cocaine non-responders, there was no significant difference in any condition 
(footshock vs. no footshock; Pitstop2 vs. vehicle) compared to the last day of extinction. 
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Hence, Pitstop2 appears only to block stress-induced reinstatement if the animal is 
cocaine experienced. 
 
BNST ERK Signaling in Stress-Induced Reinstatement 
As mentioned above, there are several mechanisms by which PAC1 receptors may 
activate MEK/ERK pathways, including PKA and PKC activation and endosomal 
signaling. Importantly, ERK phosphorylation has been attenuated by blocking PAC1 
receptor internalization into signaling endosomes (Merriam et al., 2013). Here, consistent 
with cell culture data (May et al., 2014; May & Parsons, 2017) and analysis in a chronic 
constriction injury model (Missig et al., 2017), pretreatment with Pitstop2, an inhibitor of 
clathrin-mediated endocytosis, prior to footshock, completely ablated pERK expression 
in cocaine responders (Figure 3.5, compare (A) and (C)). In cocaine responders, 
compared to no-footshock, footshock stress increased the number of activated 
phosphorylated ERK neurons (Figure 3.5, compare (A) and (B)). Pretreatment with 
Pitstop2 blocked the ability of footshock stress to induce ERK phosphorylation in BNST 
neurons (Figure 3.5, (C)). Indeed, the increase in footshock-stimulated ERK activation 
was attenuated approximately 80-90% by Pitstop2 (vehicle + footshock = 122.22 ± 17.3 
cells vs. Pitstop2 + footshock = 11.2 ± 2.54 cells, [Bonferroni’s m.c. t(15)=5.57, 
p<0.0001]). Furthermore, there was a significant interaction between pre-treatment 
(vehicle vs. Pitstop2) by stress (footshock vs. no footshock) interaction, F(2,15)=5.19, 
p<0.05. Notably, there was also a difference in pERK expression in animals who did not 
receive stressor exposure, but were cocaine experienced (Figure 3.5, compare (B) and 
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(F); vehicle + no-shock = 43.2 ± 12.4 cells vs. Pitstop2 + no-shock = 14.44 ± 17.3 cells, 
[Bonferroni’s m.c. t(15)=1.23, NS]). Figure 3.5 (I) and (J) shows quantified pERK levels 
in cocaine responders vs. non-responders after footshock vs. no-footshock and vehicle vs. 
Pitstop2 pretreatment. 
 
Regarding cocaine non-responders, there was no significant difference between any of 
the conditions (footshock vs. no-footshock or vehicle vs. Pitstop2; Figure 3.5 (E-H, J)). 
Interestingly, there is a slight, but insignificant, increase in pERK expression in cocaine 
non-responders who receive vehicle treatment paired with footshock, likely due to the 
footshock stress prior to perfusion for tissue harvest. This is notable, as footshock only 
appears to significantly increase pERK if the animal is cocaine experienced, a finding 
that may be PACAP dependent. Average cell counts for cocaine non-responders are as 
follows: group vehicle + shock = 45.89 ± 19.84; shock + Pitstop2 = 5.08 ± 4.32; no-
shock + vehicle = 14.44 ± 7.89; no-shock + Pitstop2 = 7.44 ± 2.32. This data may suggest 
a permanent change in the PACAP system following cocaine exposure.  
 
4.4. Discussion 
 
In Experiment 1, we showed that BNST PAC1 receptor activation is necessary for stress-
induced reinstatement, as selective PAC1 receptor agonist maxadilan infusion caused 
drug-seeking on test day in the absence of stress. Then, Experiment 2 showed that shock-
induced pERK signaling is dependent on PAC1 receptor activation. Here, we show that 
blockage of clathrin-mediated endocytosis by Pitstop2 attenuated drug-seeking in the 
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presence of footshock stress. Furthermore, we saw a decrease in pERK activation 
following footshock stress after Pitstop2 pretreatment, indicating an importance of 
downstream PAC1 mechanisms in ERK activation that may lead to further neuronal 
activity responsible for relapse states. 
 
 As a group, G-protein coupled receptors (GPCRs) function primarily to transduce 
extracellular stimuli into intracellular signals. Following agonist binding to the receptor 
(PACAP to PAC1), a change in the conformation of the PAC1 receptor occurs that 
facilitates activation of downstream pathways. This signaling may be attenuated by 
internalization of the receptor (an action likely facilitated by arrestin binding) or removal 
of the agonist. Additionally, PAC1 internalization may facilitate sustained MEK/ERK 
activation. Here, we blocked clathrin-mediated endocytosis and attenuated stress-induced 
reinstatement of drug-seeking in addition to decreasing ERK phosphorylation. Recently, 
Missig et al. (2017) showed that Pitstop2 pretreatment blocks PACAP-stimulated 
receptor internalization and behavioral manifestations of pain in a chronic constriction 
injury model. Finally, in an electrophysiology preparation, Pitstop2 ablates PACAP-
induced increases in cardiac neuron excitability (Merriam et al., 2013; May & Parsons, 
2017).  
 
The ability to inhibit clathrin-mediated endocytosis would benefit studies in both cell 
biology and in the clinical realm. The Pitstop compounds, while they provide some 
insights into cell physiology, also have their drawbacks: Pitstop2 is a global inhibitor of 
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clathrin-mediated endocytosis and is therefore not selective to the PAC1 receptor. Willox 
et al. (2014) tested the extent of Pitstop2 non-specificity and found that the compound 
acts very differently in vivo than in cell culture. In vitro, Pitstop2 binds to the receptor 
pocket that accommodates clathrin-box motif peptides, whereas the compound does not 
bind (or binds with lower affinity) at this site in vivo, lessening the effects of Pitstop2. In 
the current experiment, there were no changes between vehicle and Pitstop2-treated 
cocaine non-responders that did not receive footshock, so we may reasonably conclude 
that clathrin-mediated endocytosis is required for BNST PACAP signaling to fully induce 
ERK phosphorylation and stress-induced reinstatement.  
 
While PACAP mediated effects have relatively gradual onsets (see Shimizu et al., 2004), 
activation of the PACAP/PAC1 compound stimulates ERK for long durations (Clason et 
al., 2016). Studies by Walker and Davis showed that the BNST likely mediates responses 
to sustained, fear-evoking stimuli (akin to anxiety), rather than short, phasic fear-evoking 
stimuli (likely mediated by CeA; Davis et al., 2010; Walker et al., 2009). Hence, BNST 
appears to play a role in sustained responding. Indeed, one possible role for PAC1 in 
addiction states is that receptor internalization may provide a mechanism to allow for 
sustained ERK activation. Theoretically, sustained ERK signaling could have 
implications in PACAP/PAC1 mediated plasticity that promotes neurochemical changes 
in response to drug use, stress, or even trauma that could lead to sustained 
psychopathologies.  
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The PAC1 receptor can also be coupled to both Gs and Gq to activate adenylyl cyclase 
(AC) and phospholipase C (PLC), respectively (for review, see Hammack & May, 2015). 
Increased AC activity results in heightened cAMP expression which engage PKA-
dependent or -independent pathways leading to ERK phosphorylation and subsequent 
signaling. In contrast, increased PLC activity leads to IP3 and DAG activation, which 
stimulates PKC mechanisms leading to ERK phosphorylation. Hence, these two 
alternative pathways stimulate mitogen-activated protein kinase (MAPK)/ERK cascades 
(that later help facilitate intra-cellular function) without associating arrestin scaffolding 
proteins that aid in receptor internalization. Thus, if we had not seen an attenuation of 
drug-seeking on test day in cocaine responders who received Pitstop2 pretreatment paired 
with stressor exposure, it might have been possible that endosomal signaling mediated by 
clathrin dependent endocytosis was not involved in stress-induced reinstatement. Since 
we did observe a decrease in active lever press responding on test day in this group of 
animals, we next blocked MEK signaling, further downstream of the PAC1 receptor in 
the intracellular signaling cascade. 
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4.5. Figures 
 
 
 
 
 
Figure 4.1. Timeline for Experiment 3. Jugular catheterizations and BNST cannulations 
were performed concurrently in rats for self-administration and test-day infusions, as 
shown in the experimental timeline. This was followed by one week of post-operative 
recovery, 10d cocaine self-administration training, 20d extinction training, and a test day. 
Infusions of Pitstop2 or vehicle treatment occurred 15 minutes prior to the animals’ 
reintroduction to the operant conditioning chambers on test day. During test, animals 
received either footshock or no footshock. Animals were perfused 30m after the end of 
their behavioral test for tissue harvest and subsequent immunohistochemistry procedures.  
 
 
Cocaine SA (10 days) Post-Op (7 days) Extinction (20 days) 
Test for footshock-induced 
reinstatement 
Jugular Catheterization & 
BNST Cannulation 
Surgeries 
Intra-BNST Infusion of Pitstop2 or Vehicle 
15 min prior to behavioral test 
Perfusion, 30 
min after test 
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Figure 4.2. BNST Cannula Placements. 
Cannula placements are depicted above such that enclosed red dots represent a 1mm 
extension beyond the tip of the cannula. Rats were included in the analysis if their 
placement resided within a portion of the BNST; they were eliminated from analysis if 
their cannulae placement fell outside the histological boundary of the BNST, fell within 
the lateral ventricles, or if animals did not complete behavioral testing.  
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Figure 4.3. Intra-BNST Pitstop2 infusion attenuates stress-induced reinstatement to 
cocaine-seeking. 
(A) Self-administration training on the active lever during Experiment 2; inactive lever 
presses remained uniformly low throughout acquisition. A median split analysis for total 
lever presses over 10d was used to separate cocaine responders (M=88.5, SD=6.12) from 
non-responders (M=25.25, SD=9.14). (B) Extinction training during Experiment 2. 
Extinction sessions occurred during the 20 days after self-administration training. (C) To 
determine whether PAC1 receptor activation is necessary during reinstatement to drug-
seeking, we infused clathrin-mediated endocytosis inhibitor Pitstop2 or vehicle into the 
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BNST paired with footshock or no footshock during the test phase of the reinstatement 
procedure. Stressor exposure only caused reinstatement to extinguished drug-seeking in 
cocaine responders who received intra-BNST vehicle solution; Pitstop2 treatment 
completely attenuated drug-seeking behavior following stressor exposure. (D) There were 
no differences between the last day of extinction and test day in cocaine non-responders, 
and no effect of vehicle vs. Pitstop2 infusion. Group n’s are as follows: cocaine 
responders-noshock-vehicle, n=5; cocaine responders-noshock-Pitstop2, n=3; cocaine 
responders-shock-vehicle, n=3; cocaine responders-shock-Pitstop2, n=3; cocaine non-
responders-noshock-vehicle, n=3; cocaine non-responders-noshock-Pitstop2, n=3; 
cocaine non-responders-shock-vehicle, n=3; cocaine non-responders-shock-Pitstop2, 
n=4. Data represent mean lever presses ± SEM. 
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Figure 4.4. Total cocaine intake over 10d acquisition. 
Cocaine responders in both the footshock/no-footshock and vehicle/Pitstop2 groups 
received the same amount of cocaine during acquisition. Vehicle/Footshock (M=34.2, 
SD=6.97); Vehicle/NoFootshock (M=31.6, SD=8.51); Pitstop2/Footshock (M=37.2, 
SD=7.86); Pitstop2/NoFootshock (M=29.2, SD=5.76). This indicates that reinstatement 
was elicited by footshock stress (rather than total cocaine intake during acquisition), and 
subsequently blocked by Pitstop2 pre-treatment. 
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Figure 4.5. PACAP receptor internalization and ERK activation participate in 
BNST-mediated reinstatement to extinguished drug seeking. 
Compared to no-stress (B), footshock stress increased the number of activated 
phosphorylated ERK neurons (A) when paired with a vehicle infusion in cocaine 
responders. Pretreatment with clathrin-mediated endocytosis inhibitor Pitstop2 (B) 
blocked the ability of stress to induce ERK phosphorylation in BNST neurons. Cocaine 
non-responders expressed very little pERK regardless of footshock stress or infusion 
treatment (E, F, G, H, J). Scale bar: 100 µm. Data represent mean cell number ±SEM.  
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CHAPTER 5: INHIBITION OF MEK PATHWAY ATTENUATES STRESS-
INDUCED REINSTATEMENT TO COCAINE SEEKING. 
 
5.1. Introduction 
 
The communication of extracellular signals (i.e. hormones, mitogens) to internal cellular 
environments happens through an intricate messaging system mediated by the binding of 
ligands and subsequent activation of specific transmembrane receptors which further 
submit signals through intracellular pathways. These pathways consist of interacting 
proteins and include the mitogen-activated protein kinase (MAPK) cascade. Signal 
transmission by MAPK proteins is often initiated by the activation of a small g-protein. 
In the case of the PAC1 receptor, Gαs activates phospholipase C (PLC) which stimulates 
protein-kinase C (PKC) dependent signaling events to activate MAPK-extracellular 
signal-related kinase (MEK) which further stimulates phosphorylation of ERK. 
Additionally, Gαq can couple to adenylyl cyclase (AC) to activate protein kinase A 
(PKA) which also activates MEK pathways, leading to phosphorylation of ERK (for 
review, see Hammack & May, 2015). Importantly, the ERK family represents a critical 
subfamily of MAPKs, as stimulation targets transmembrane proteins and transcription 
factors (Chen et al., 2013) The mitogen-activated protein kinases are a well conserved 
family of kinases involved in numerous cellular processes including proliferation, 
motility, development, and differentiation (Shaul & Seger, 2007). 
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PD98059 is a highly selective inhibitor of MEK activation and, subsequently, the MAPK 
signaling cascade (Crews et al., 1992; Rosen et al., 1994; Cowley et al., 1994), and acts 
by preventing activation of MEK1 and MEK2 by upstream proteins. It has been widely 
used across scientific fields and has been shown to accelerate differentiation (Hotokezaka 
et al., 2002), prevent degeneration (Rapoport & Ferreira, 2000), attenuate synaptic 
plasticity (Coogan et al., 1999), promote cell migration (Zhao et al., 2017), and influence 
immune factors that mediate behavior (Rojewska et al., 2015). Hence, the MAPK 
signaling pathway can facilitate numerous intracellular events, and is an important 
proposed target in the treatment of physiological disorders. Indeed, pathway inhibitors 
have been widely used to block specific pathways to observe changes in effects in 
different experimental procedures. PD98059 has high selectivity for the MEK pathway, 
and results in clear changes in downstream protein expression after application (Gregg & 
Frazier, 2011). 
 
In an effort to elucidate mechanisms underlying PACAP- and stress-induced cellular 
responses, Clason et al. (2016) showed that PD98059 application can suppress PACAP-
stimulated increases in guinea pig cardiac neuron excitability (see also Tompkins et al., 
2016). Furthermore, Missig et al. (2017) showed that CeA pretreatment with PD98059 
decreased PACAP-mediated c-fos and pERK immunoreactivity and heightened 
nociception sensitivity: PACAP-induced responses were completely abolished by MEK 
inhibition, demonstrating a necessity for PACAP/PACI signaling via ERK pathways in 
amygdala pain responses. As expressed in Chapter 3, PACAP/PAC1 receptor-mediated 
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ERK activation may be largely controlled by endosomal signaling and PAC1 receptor 
internalization. Indeed, blockade of receptor internalization by clathrin-mediated 
endocytosis inhibitor Pitstop2 successfully attenuated both behavioral manifestations of 
stress-induced reinstatement (see Figure 4.3) and subsequent ERK phosphorylation (see 
Figure 4.5). Hence, endosome g-protein coupled receptor signaling via the PAC1 receptor 
appears to have important physiological functions in stress-related disorders including 
chronic pain and relapse to drug-use. 
 
Together, Experiments 1, 2 & 3 (Chapters 2, 3 & 4, respectively) suggest that stress-
induced reinstatement is BNST PAC1-receptor mediated and likely involves the 
downstream activation of circuits associated with stress responses. In this experiment, we 
sought to examine whether inhibition of MEK could mitigate stress-induced 
reinstatement to drug-seeking and diminish ERK phosphorylation following stressor 
exposure. As noted above, we and others have shown that PACAP signaling can activate 
MEK/ERK, a key mechanism in synaptic plasticity involved in many CeA-dependent 
behaviors. As the CeA and BNST share similar morphologies, we hoped to assess BNST 
PAC1 receptor mechanisms in vivo and hypothesized that endogenous PACAP signaling 
in the BNST and resulting PAC1 receptor-mediated ERK activation mediates stress-
induced drug-seeking in rodents. As with prior experiments mentioned, we hoped to 
establish whether BNST PACAP signaling via ERK could evoke stress-induced 
reinstatement and utilized the MEK inhibitor PD98059 to block mitogen activated protein 
kinase cascades that stem from the PAC1 receptor and may play a role in controlling cell 
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growth and differentiation. We hypothesized that MEK inhibition prior to stressor 
exposure (footshock stress) would prevent stress-induced reinstatement in cocaine 
experienced animals compared to animals who receive vehicle treatment infusion. 
 
5.2 Materials & Methods 
 
Subjects, Apparatus & Surgical Procedures 
Thirty-two naïve male Sprague Dawley rats of the same age and from the same vendor as 
those described in Experiments 1, 2 & 3 (Chapters 2, 3 & 4 respectively) were used in 
this experiment. They were maintained under the same conditions and utilized the same 
apparatus as that used in Experiments 1, 2 & 3. All animals received both the jugular 
catheterization and BNST cannulation surgeries as described above. 
 
Cocaine Self-Administration (Acquisition) 
As in Experiment 1, animals were allowed to lever press for cocaine hydrochloride 
(0.3mg/ml, obtained from the same vendor as in Experiment 1) during daily 1 h sessions 
for 10 days according to a fixed ratio schedule of reinforcement. Animals received the 
same conditions inside the operant chamber as animals in Experiment 1.  
 
Extinction 
Extinction sessions proceeded as described in Experiment 1. 
 
Reinstatement 
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On the day following the last day of extinction, rats were split into four groups, 
counterbalanced for order and time of testing, that received different treatments. Rats 
received an infusion into the BNST of MEK inhibitor PD98059 (20 µM, Tocris 
Bioscience, Bristol, UK) or equivolume 0.05% BSA saline vehicle paired with footshock 
or no footshock in an effort to observe the effects of inhibition on downstream PAC1 
receptor targets. Directly following bilateral infusion, animals were placed into the 
operant conditioning chambers and allowed to lever press. Active and inactive levers 
were available and presses recorded, but no drug was available during the test day. 
Animals were broken into groups based on three factors: Cocaine vs. Non Cocaine 
responders, Footshock vs. No Footshock, and MEK inhibitor PD98059 vs Vehicle 
solution. Hence, the groups were as follows: Responders-Shock-PD98059, n=4; 
Responders-Shock-Vehicle, n=4; Responders-NoShock-PD98059, n=4; Responders-
NoShock-Vehicle, n=4; NonResponders-Shock-PD98059, n=4; NonResponders-Shock-
Vehicle, n=4; NonResponders-NoShock-PD98059, n=2; and NonResponders-NoShock-
Vehicle, n=4. 
 
Histological and Immunohistochemistry Procedures 
Thirty minutes after the test session, animals were deeply anesthetized with Beuthanasia-
D (sodium pentobarbital; Zoestis, Kalamazoo, MI) solution and perfused transcardially 
with saline followed by 4% paraformaldehyde. Brains were postfixed for 24 h, washed 
and equilibrated in 30% sucrose before embedding in optimal cutting temperature (OCT) 
compound (ThermoFisher Scientific, Waltham, MA) for cryosectioning (40 µm). All 
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sections were mounted onto subbed slides, permabilized with 0.3% Titron X-100, 
blocked with 1% BSA, and incubated in primary antibody (1:1000, Phospho-p44/42 
MAPK (Erk1/2) Rabbit monoclonal antibody, #4370 Cell Signaling Technology, 
Danvers, MA) for visualization of pERK using species specific AlexaFluor 488 (1:500; 
4hr; ab150077; Abcam). 
 
Image Analysis 
Micrographs were obtained using a 10x objective on an Olympus fluorescence 
microscope (Nikon Instruments, Melville, NY) with identical parameters for each image. 
For quantification of BNST pERK immunoreactivity, the corresponding BNST fields in 
the different brains were identified using the anterior commissure, lateral ventricles, and 
outer field of the caudate putamen as reference points; area of threshold was used as an 
indicator of relative fluorescence from same sized fields. For enumeration of BNST 
pERK in fixed areas, a semi-autonomous cell counting method was performed in 
StereoInvestigator (MBF Biosciences, Williston, VT). All data represent mean values ± 
SEM. 
 
Data Analysis 
All statistical tests were performed in SPSS (version 22) and GraphPad PRISM (version 
6). Two-way analysis of variance (ANOVA) was performed to examine main effects and 
interactions, and Bonferroni’s multiple comparison tests were used to compare different 
groups for all experiments, except where indicated. 
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5.3. Results 
 
Together, the first three experiments suggest that stress-induced reinstatement is BNST 
PAC1-receptor mediated and likely involves the downstream activation of circuits 
associated with stress responses (see Figure 1.5). In this experiment, we examined 
whether inhibition of MEK mitigated stress-induced reinstatement to drug seeking. We 
and others have shown that PACAP signaling can activate mitogen-activated protein 
kinase/ERK, a key mechanism in synaptic plasticity and involved in many CeA-
dependent behaviors (see Battle et al., 2016; Rosas et al., 2017; Huynh et al., 2017; 
Huang & Lin, 2006; Herry et al., 2006; Missig et al., 2017). Furthermore, May & Parsons 
(2017) recently suggested that PAC1 receptor endocytosis may be critical for PAC1 
signaling (see Chapter 4) and subsequent activation of downstream signaling molecules, 
such as MEK. Recently, Missig et al., (2017) demonstrated that CeA pretreatment with 
MEK inhibitor PD98059 significantly attenuated PACAP-stimulated thermal 
hypersensitivity, indicating that ERK activation may be an essential component of 
PACAP-instigated CeA activity. As the CeA and BNST share similar morphologies, we 
assessed BNST PAC1 receptor mechanisms in vivo and hypothesized that endogenous 
PACAP signaling in the BNST and resulting PAC1 receptor-mediated ERK activation 
mediates stress-induced reinstatement of drug seeking in rodents. Hence, we sought to 
establish whether BNST PACAP signaling via ERK could evoke stress-induced 
reinstatement and utilized the MEK inhibitor PD98059 to block mitogen activated protein 
kinase cascades that stem from the PAC1 receptor and may play a role in controlling 
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cell growth and differentiation. 
 
BNST PACAP signaling facilitates stress-induced reinstatement to extinguished cocaine 
seeking 
Figure 5.1 illustrates a timeline of events for Experiment 4. Data from 30 animals were 
used in the analyses for the tests for reinstatement, as post-test histological examination 
of injection sites for these rats were found to be placed appropriately in the BNST. One 
animal had an improperly placed cannulae, and another died during extinction training; 
these animals were excluded from all analyses. Figure 5.2 portrays the distribution of 
cannula placements in analyzed animals.  
 
A median split analysis for total lever presses over 10d was used to separate cocaine 
responders (M=36.85, SD=6.61) from non-responders (M=8.45, SD=1.12). Cocaine 
responders lever pressed almost solely on the active lever that produced cocaine delivery; 
hence, active and inactive lever presses differed by the end of acquisition (Figure 5.3 
(A)). In contrast, cocaine non-responders did not consistently press the active lever, and 
there was no significant difference in responding on the active vs. inactive levers during 
acquisition. By the end of extinction, all animals had reached ≤ 5 responses on the active 
lever (Figure 5.3 (B)); inactive lever presses remained uniformly low throughout 
extinction. The mean (± SEM) number of responses made on the active and inactive 
levers on the last day of extinction and during the test for reinstatement is shown in 
Figure 5.3 (C, D).  
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A repeated measures ANOVA for inactive lever press responses did not reveal significant 
results. Regarding active lever presses, there was a significant main effect of session 
between the last day of extinction and testing (F(3, 16) = 6.33, p<0.01) in cocaine 
responders. There were also significant interactions between session and shock 
(F(1,16)=9.73, p<0.05) and session and infusion treatment (F(1, 16)=11.56, p<0.01). 
Finally, there was a significant session by shock by infusion treatment interaction, (F(3, 
16)=11.46, p<0.001), consistent with the fact that only cocaine-responding animals who 
received the footshock and vehicle infusion demonstrated stress-induced reinstatement. 
Importantly, animals in both the vehicle and PD98059 groups received the same amount 
of cocaine during acquisition (Figure 5.4), indicating that reinstatement was elicited by 
footshock exposure rather than total cocaine intake during acquisition. There were no 
significant differences between the last day of extinction and test in cocaine non-
responders, nor were there any significant effects of infusion treatment or stressor 
exposure. Hence, PD98059 blocked reinstatement of extinguished cocaine seeking when 
the rats were exposed to a stressor only if the animals had successfully learned the lever-
press/cocaine-infusion association. The post hoc analysis comparing antagonist and 
vehicle infusion on total responses on active lever responses after footshock exposure 
revealed significantly less responding in the PD98059 condition (p<0.05). Furthermore, 
the number of responses on the active lever in the no-footshock conditions after 
injections of PD98059 did not differ from lever press activity after vehicle infusion in 
either cocaine responders or non-responders. Neither the MEK inhibitor nor the vehicle 
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treatment altered responding on inactive lever presses (F(1,16)=4.23, NS) and responses 
remained uniformly low during testing. 
 
BNST MEK/ERK signaling in stress-induced reinstatement 
As mentioned above, the effects of BNST PAC1 receptor activation are likely mediated 
by intracellular signaling cascades that manifest in increased pERK expression. 
Footshock paired with vehicle treatment significantly elevated pERK levels in cocaine 
responders 30 min after test (F(1,12)=5.01, p<0.01; Figure 5.5 (A, I)). Footshock induced 
a robust increase in the number of pERK cells in the anterolateral BNST in cocaine 
responders, with almost no pERK labeling in non-responders under the same conditions 
(main effect of stress, F(1,12)=5.16, p<0.05; Figure 5.5 (E, J)). While footshock appears 
to result in marked increases in BNST pERK immunoreactivity, pretreatment with MEK 
inhibitor PD98059 completely abolished the footshock-stimulated response; hence, where 
we would expect to see high levels of pERK cells due to footshock stress, there was very 
little expression (vehicle + footshock =105.33 ± 17.76 vs. PD98059 + footshock = 5.75 ± 
4.32, [bonferroni’s m.c. t(14)=4.12, p<0.001]; Figure 5.5 (C, I)). Interestingly, some 
pERK expression was observed in cocaine responders who received vehicle treatment 
and no-footshock (Figure 5.5 (B, I)), suggesting that there may be a permanent change in 
the PACAP system (i.e. sensitization) following cocaine exposure. In animals who did 
not receive footshock stress, pERK levels were significantly lower in those who received 
PD98059 compared to vehicle treatment (F(1,12)=4.71, p<0.05), demonstrating that 
PD98059 may block all MEK in the area after infusion (vehicle + no-footshock = 39.01 ± 
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5.83 vs. PD98059 + no-footshock = 5.25 ± 1.40). ERK activation may be an essential 
component of PACAP signaling to instigate BNST neuronal activity, and PACAP/PAC1 
receptor signaling via ERK pathways may be critical to stress-induced reinstatement 
processes.  
 
Regarding cocaine non-responders, there was no significant difference between any of 
the conditions (footshock vs. no-footshock or vehicle vs. PD98059). Average cell counts 
for cocaine non-responders are as follows: group vehicle + shock = 16.75 ± 3.33; 
PD98059 + shock = 4.5 ± 1.21; vehicle + no-shock = 5.75 ± 2.15; PD98059 + no-shock = 
5.5 ± 0.50 (Figure 5.5 (E-H, J)). 
 
5.4. Discussion 
 
In succession, these experiments establish a role for BNST PACAP signaling as a 
mediator of stress-induced reinstatement to drug-seeking. In Experiment 1, we showed 
that selective PAC1 agonist, maxadilan, infusion into the BNST caused reinstatement in 
the absence of stressor exposure, demonstrating a critical role of the PAC1. Experiment 2 
highlighted the role of PAC1 receptor activation in stress-induced pERK expression. 
Then, we showed that blocking PAC1 receptor internalization by clathrin-mediated 
endocytosis inhibitor Pitstop2 successfully attenuated reinstatement after stressor 
exposure and ablated ERK phosphorylation. Since PAC1 receptor endocytosis is 
upstream of MAPK/ERK signaling, here we blocked MEK pathways using MEK 
inhibitor PD98059 and saw an abrogation of reinstatement after footshock and a 
 104 
subsequent decrease in pERK expression. Together, these results further our 
understanding of central nervous system PACAP mechanisms and point to the 
PACAP/PAC1 system as an important part of the circuit that modulates stress and reward 
pathways. As discussed below, the dysregulation of this system could lead to 
psychopathologies related to stress and reward systems, such as relapse to drug use. 
 
The ability of MEK inhibition to lessen BNST-mediated stress-induced pERK in parallel 
with behavioral blockade of reinstatement demonstrates that PACAP/PAC1 receptor 
mediated ERK activation is a critical component for BNST relapse responses. As 
discussed above, there are several routes by which PAC1 receptors can activate MEK 
including short-acting adenylyl clcyase/cAMP and PLC/PKC. However, recent 
experiments demonstrating PAC1 receptor endocytosis (Merriam et al., 2013; Missig et 
al., 2017; May & Parsons, 2017) as a means to activate MEK may represent a critical 
mechanism for prolonged PAC1 receptor activation. In a similar fashion to the MEK 
inhibitor, Pitstop2 blocked stress-induced reinstatement and corresponding pERK 
activation. Together, this could implicate the importance of GPCRs (specifically PAC1) 
and endosomal signaling in the physiology underlying relapse. In summary, g-protein 
independent signaling via receptor-arrestin scaffolding and subsequent assembly of 
internal signaling complexes leads to sustained MEK/ERK activation, which we can 
inhibit using PD98059 or Pitstop2.  
 
Addiction to drugs of abuse is often characterized by a chronic cycle of drug intoxication, 
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withdrawal and relapse. The biological mechanisms that underlie these phases are largely 
unclear but may involve signaling by ERK and other members of the MAPK family. 
Indeed, cocaine exposure increases ERK activation in the VTA, amygdala, BNST, and 
regions of the prefrontal cortex (Lu et al., 2006). Repeated (but not acute) cocaine 
administration itself has been shown to alter ERK phosphorylation (Valijent et al., 2000) 
in the striatum and nucleus accumbens, and an upstream MEK inhibitor (SL327) blocked 
this effect. Brami-Cherrier et al. (2005) also reported an effect of SL327 on ERK activity, 
downstream CREB activity, and the activity of an intermediary kinase in the dorsal 
striatum and nucleus accumbens. Additionally, Lu et al. (2005) showed that basolateral 
amygdala ERK phosphorylation was increased during periods of withdrawal. 
Furthermore, Ferguson et al. (2006) found that MEK inhibition affects cocaine 
conditioned place preference (CPP), and ERK1 knockout mice show enhanced morphine 
CPP (Mazzucchelli et al., 2002) which suggests a role of the accumbens in cocaine 
reward. Indeed, Miller & Marshall (2005) prevented CPP and blocked ERK activation by 
infusing PD98059 into the accumbens. ERK activity may also contribute to psychomotor 
sensitization after cocaine administration as indicated by studies completed looking at the 
role of the VTA (Lu et al., 2006), as cues associated with drug use may rely on ERK for 
memory consolidation. While these studies and others point to an important role of ERK 
in drug self-administration, additional research is needed to elucidate the distinct roles in 
ERK activity in drug acquisition, extinction (i.e. withdrawal), and relapse (cue-induced, 
drug-induced, or stress-induced). The current experiment highlights an important role of 
BNST PACAP/PAC1 signaling in downstream ERK signaling and subsequent cell 
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proliferation, differentiation, or motility. 
 
We have previously shown that intra-BNST PACAP6-38 (PAC1/VPAC2 receptor 
antagonist) infusion attenuates stress-induced reinstatement to drug seeking (Figure 1.2; 
Miles et al., 2017). We’ve also shown that PAC1 receptor activation leads to intracellular 
signaling cascades that result in increased pERK expression (Chapter 2). Hence, stress-
induced reinstatement, when acting through PAC1 mechanisms, should increase pERK 
expression, and blockade should ablate ERK phosphorylation. Hence, Experiment 4 
sought to test the effects of stressor exposure on reinstatement (effectively recapitulating 
results from Miles et al., 2017) and subsequent pERK activation. 
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5.5. Figures 
 
 
 
 
 
Figure 5.1. Timeline for Experiment 4. Jugular catheterizations and BNST cannulations 
were performed concurrently in rats for self-administration and test-day infusions, as 
shown in the experimental timeline. This was followed by one week of post-operative 
recovery, 10d cocaine self-administration training, 20d extinction training, and a test day. 
Infusions of PD98059 or vehicle treatment occurred 15 minutes prior to the animals’ 
reintroduction to the operant conditioning chambers on test day. During test, animals 
received either footshock or no-footshock. Animals were perfused 30m after the end of 
their behavioral test for tissue harvest and subsequent immunohistochemistry procedures. 
Cocaine SA (10 days) Post-Op (7 days) Extinction (20 days) 
Test for footshock-induced 
reinstatement 
Jugular Catheterization & 
BNST Cannulation 
Surgeries 
Intra-BNST Infusion of Maxadilan or 
Vehicle 15 min prior to behavioral test 
Perfusion, 30 
min after test 
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Figure 5.2. BNST Cannula Placements. 
Cannula placements are depicted above such that enclosed red dots represent a 1mm 
extension beyond the tip of the cannula. Rats were included in the analysis if their 
placement resided within a portion of the BNST; they were eliminated from analysis if 
their cannulae placement fell outside the histological boundary of the BNST, fell within 
the lateral ventricles, or if animals did not complete behavioral testing.  
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Figure 5.3. Intra-BNST infusion of MEK Inhibitor PD98059 attenuates stress-
induced reinstatement. 
(A) Self-administration training on the active lever during Experiment 3; inactive lever 
presses remained uniformly low throughout acquisition. A median split analysis for total 
lever presses over 10d was used to separate cocaine responders (M=36.85, SD=6.61) 
from non-responders (M=8.45, SD=1.12). (B) Extinction training during Experiment 3. 
Extinction sessions occurred during the 20 days after self-administration training. (C) To 
determine whether PAC1 receptor activation is necessary during reinstatement to drug-
seeking, we infused mitogen activated protein kinase-ERK inhibitor PD98059 or vehicle 
into the BNST paired with footshock or no footshock during the test phase of the 
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reinstatement procedure. Stressor exposure only caused reinstatement to extinguished 
drug-seeking in cocaine responders who received intra-BNST vehicle solution; PD98059 
pre-treatment completely attenuated drug-seeking behavior following stressor exposure. 
(D) There were no differences between the last day of extinction and test day in cocaine 
non-responders, and no effect of vehicle vs. PD98059 infusion. Group n’s are as follows: 
cocaine responders-noshock-vehicle, n=4; cocaine responders-noshock-PD98059, n=4; 
cocaine responders-shock-vehicle, n=4; cocaine responders-shock-PD98059, n=4; 
cocaine non-responders-noshock-vehicle, n=4; cocaine non-responders-noshock-
PD98059, n=2; cocaine non-responders-shock-vehicle, n=4; cocaine non-responders-
shock-PD98059, n=4. Data represent mean lever presses ± SEM. 
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Figure 5.4. Total cocaine intake over 10d acquisition. 
Animals in groups Vehicle/Footshock (M=42.71, SD=6.67), Vehicle/NoFootshock 
(M=35, SD=7.07), PD98059/Footshock (M=41.5, SD=8.93), and PD98059/NoFootshock 
(M=28.2, SD=4.46) received the same amount of cocaine during acquisition, indicating 
that reinstatement was elicited by footshock stress rather than total cocaine intake during 
acquisition.  
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Figure 5.5. BNST pretreatment with MEK inhibitor PD98059 blocks stress-induced 
ERK phosphorylation. 
Compared to no-stress (B, D, I), footshock stress increased the number of activated 
phosphorylated ERK neurons in cocaine responders (A, I). Pretreatment with MEK 
inhibitor PD98059 blocked the ability of stress to induce ERK phosphorylation in BNST 
neurons (C, I). In cocaine non-responders, there was a slight, but insignificant increase in 
pERK expression in animals who received vehicle treatment paired with footshock (E, J), 
which was blocked by PD98059 (G, J). There was very little pERK expression in cocaine 
non-responders who did not receive footshock stress, regardless of infusion treatment (F, 
H, J). Scale bar: 100 µm. Data represent mean cell number ±SEM.  
I J 
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CHAPTER 6: GENERAL DISCUSSION 
 
The studies in this dissertation were aimed to investigate the role of BNST PACAP 
signaling in mediating stress-induced reinstatement to drug-seeking. In humans, relapse 
to drug-use if often triggered by a stressful event. Furthermore, addiction is co-morbid 
with many disorders of mood and anxiety, and the limited data in human drug abusers 
indicate a reasonable correlation between animal models of reinstatement and drug 
relapse in humans. In both humans and animals, drugs appear to activate the BNST, and 
several abusive substances elicit symptoms of anxiety and panic (Singewald, Salchner & 
Sharp, 2003) likely due to their activation of the HPA axis. As PACAP and PAC1 
receptors are highly expressed in brain areas that modulate HPA axis activity, we propose 
PACAP systems may be a critical component underlying stress-induced reinstatement 
and developed these dissertation experiments to elucidate the key signaling molecules 
and neural circuits involved in relapse behaviors.  
 
The four experiments described here establish a role for BNST PACAP signaling as an 
effector of physiological and behavioral manifestations of stress-induced relapse. First, 
we mimicked stress-induced reinstatement by infusing selective PAC1 receptor agonist, 
maxadilan, into the BNST in the absence of footshock exposure. This completely 
recapitulated previous results (Miles et al., 2017) showing that PACAP infusion itself 
into the BNST is sufficient to cause reinstatement to extinguished cocaine-seeking 
behavior and provided evidence for PAC1 receptor activation (rather than VPAC2, which 
also binds PACAP) in stress-induced relapse processes. We then showed that 
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blockade of endogenous PACAP signaling during a test for reinstatement using 
PACAP6-38 attenuated stress-induced reinstatement and decreased pERK expression in 
the BNST. Finally, we showed that BNST ERK activation was diminished upon 
pretreatment with clathrin-mediated endocytosis inhibitor Pitstop2 (Experiment 3) or 
MEK inhibitor PD98059 (Experiment 4) in conjunction with a decrease in behavioral 
manifestations of reinstatement (i.e. increased lever pressing on the lever previously 
associated with cocaine delivery). This finding further supports the role of PAC1 receptor 
activation in relapse processes, as blockade of downstream targets both prevented relapse 
and reduced ERK phosphorylation. These results aid in our understanding of central 
nervous system PACAP mechanisms and demonstrate that detrimental adaptations to the 
BNST PACAP system may negatively affect the outcome of individuals striving to 
abstain from drug use.  
 
6.1. The role of BNST in addiction 
 
 
The BNST has been widely cited as a center for integration between stress-related 
regions, including the BLA, CeA, and PVN, and reward centers like the NAcc or VTA 
(Jalabert et al., 2009; Georges & Aston-Jones, 2001, 2002). Indeed, BNST function may 
serve as a critical modulator of drug-related behaviors as lesions to the area prevent cue- 
and stress-induced reinstatement to drug-seeking (Buffalari & See, 2011; McFarland et 
al., 2004). Electrophysiological studies have also suggested heightened synaptic plasticity 
within the BNST in response to drug use: cocaine self-administration increases 
AMPA/NMDA ratios (Dumont et al., 2005), and alcohol intake increases NMDA 
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receptor efficiency (Kash et al., 2009; Wills et al., 2012), both markers of excitatory 
strength. Hence, drug-taking may increase activity in excitatory synapses in the BNST, 
but the specific intra-BNST regions and circuitry that underlie these enhancements has 
not been well studied. 
BNST afferent signaling 
 
The BNST receives both excitatory and inhibitory signals from multiple, widespread 
brain regions. Notably, both glutamatergic (mainly from cortical regions) and 
GABAergic innervation (predominately from CeA) drive the BNST but appear to 
mediate different behavioral outputs. Indeed, inhibition of glutamatergic inputs to the 
BNST results in a reduction of behavioral anxiety (Kim et al., 2013), whereas 
GABAergic inhibition results in a disconnect in the feedback circuitry between BNST 
and CeA that leads to decreased fear responses (Walker & Davis, 2008; Walker et al., 
2009). Alterations to either glutamate or GABA signaling could increase behavioral 
responding to stressor exposure, which may be implicated in stress-induced reinstatement 
to drug-seeking. 
 
As mentioned above, the BNST receives strong noradrenergic signaling from several 
BNST-adjacent brain regions, including the ventral noradrenergic bundle. NE-signaling 
within the BNST could influence behaviors related to addiction, as shown in several 
conditioned place preference and stress-induced reinstatement studies (Erb et al., 2000; 
Wang et al., 2001). Indeed, complex associations exist between norepinephrine and 
BNST GABAergic vs. glutamatergic signaling, but the role of norepinephrine 
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in relapse remains unknown. Serotonergic and dopaminergic connections also innervate 
the BNST, although have been shown to influence the rewarding aspects of drug taking 
rather than the negative aspects. For example, cocaine administration increases 
glutamatergic signaling at CRH receptors in the dorsolateral BNST (Kash et al., 2008) 
and decreases inhibitory signaling in the BNST (Krawczyk et al., 2011), both which may 
mediate the reinforcing effects of drugs of abuse. Similarly, serotonergic input from the 
dorsal raphe nucleus (Phelix et al., 1992) could impact addiction-related behaviors. 
Recently, Rainnie and colleagues (Guo et al., 2009) showed that stress alters the 
expression of serotonin receptors in BNST neurons; since addiction and anxiety-related 
disorders are often co-morbid, serotonin inputs may mediate behaviors associated with 
different phases of addiction. 
 
Similarly, several peptides have been shown to innervate the BNST and affect cellular 
and circuit-based activity within the extended amygdala. In addition to CRH (discussed 
above), neuropeptide Y (NPY), orexin and dynorphin also innervate the region and may 
be involved in stress-induced relapse. Indeed, CRH infusion within the BNST facilitates 
stress-induced relapse, but infusion of CRH antagonists attenuates reinstatement (Erb & 
Stewart, 1999; Wang et al., 2006), and NPY involvement has been implicated in stress- 
and anxiety-related behavior in mouse models (Pleil et al., 2012). 
 
BNST efferent signaling 
 
The BNST sends both inhibitory and excitatory projections to several 
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addiction-related brain regions. Most notably, BNST sends GABAergic and 
glutamatergic signals to the VTA, PVN, and regions of the hypothalamus, such that 
several studies have shown increases in c-fos staining (a marker of neuronal activation) in 
the BNST-VTA neural circuit following stressor exposure in a reinstatement paradigm 
(Briand et al., 2010) and similarly increased c-fos levels in the lateral hypothalamus after 
morphine withdrawal (Aston-Jones & Harris, 2004; Sartor & Aston-Jones, 2012) 
indicating that some regions that receive projections from BNST may be involved in 
components of addiction. Furthermore, projections to the PVN may be critical in 
activating the HPA axis and, therefore, may be important in stress-induced relapse 
processes. Indeed, the PVN receives GABAergic projections from the BNST (Dong et 
al., 2001; Dong & Swanson, 2006), and several studies have shown that acute stressor 
exposure (including acute cocaine injection) can increase CRH mRNA transcripts 
(Rotllant et al., 2007; Hammack et al., 2009). Because CRH signaling plays such a 
crucial role in activation of HPA axis after stressor exposure, we propose that BNST 
neurons (specifically PACAPergic neurons) may synapse onto CRH neurons in the PVN 
and induce stress-related behavioral responses. In contrast to this idea, several studies 
have shown that acute stressor exposure does not alter PACAP transcript levels, so it may 
be that chronic stress, or chronic drug-use, is necessary to activate PVN CRH. Indeed, 
our laboratory has shown that chronic stress can increase PACAP and PAC1 receptor 
transcripts in the PVN and BNST (Hammack et al., 2009), and we know that PACAP 
infusions directly into the BNST can mimic behavioral effects of chronic stressor 
exposure (increased startle responses; anxiety-like behaviors on elevated plus maze and 
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open field tests for anxiety; anorexic-like behaviors; increased corticosterone levels; 
Hammack et al., 2009; Roman et al., 2014; Lezak et al., 2014; Kocho-Schellenberg et al., 
2014). Importantly, these behavioral responses could all be attenuated by administration 
of the PAC1/VPAC2 receptor antagonist, PACAP6-38.  
 
BNST in the Dark Side of Addiction 
 
Koob and colleagues (Koob & Le Moal, 2001; Koob & Le Moal, 2008; Koob, 2015; 
Koob & Volkow, 2016) have proposed a hypothesis termed the “dark side of addiction” 
and characterized by the development of negative emotional states that may lead to 
negative reinforcement states in addiction-related physiology, behavior, and 
psychopathologies. From his work, two primary theories have emerged regarding the 
neurocircuitry that leads to the negative affect (i.e. withdrawal) stage of addiction: a 
within-system neuroadaptation due to drug use that lessens involvement of brain reward 
systems, and a between-system neuroadaptation that increases the involvement of stress-
related brain systems, including regions of the extended amygdala such as the BNST. 
Indeed, as withdrawal symptoms develop and progress, brain stress systems become 
more prevalent than brain reward systems and include the activation of CRH (Koob & Le 
Moal, 2001), norepinephrine (Carlezon et al., 2000), and PACAP (Miles et al., 2017) 
peptides that drive negative emotional states. Hence, an increase in stress system 
responding paired with a decrease in pleasure from reward systems provides substantial 
motivation for abstaining drug users to reinstate drug-taking. 
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The “dark side of addiction” may also drive an antireward system, such that 
neuroadaptations may occur after drug use that serve to limit reward (Koob & le Moal, 
1997; Koob & Le Moal, 2008). Indeed, Koob (2008, 2015) argues that brain stress 
systems may be engaged to combat the negative effects of abusive drugs and help restore 
the body’s homeostasis. As mentioned, both the HPA axis and extended amygdala brain 
regions are altered by drug self-administration, and researchers have reported increased 
levels of corticosterone, adrenocorticotropic hormone, and CRH during periods of 
withdrawal (Heilig et al., 1994; Koob, 2009). In animal models, many of the behavioral 
consequences of stressor exposure can be reduced by CRH antagonist administration 
during withdrawal (Navarro-Zaragoza et al., 2010). Hence, anxiogenic-like responses in 
elevated plus maze during withdrawal are attenuated with CRH antagonist administration 
(Sarnyai et al., 1995); conditioned place aversion to drugs of abuse can be reversed with 
CRH antagonists (Hand et al., 1988; Contarino & Papaleo, 2005); and reward thresholds 
produced by drug withdrawals are reduced with CRH antagonist administration 
(Bruijnzeel et al., 2010). Our lab and others (Tsukiyama et al., 2011; Hammack & May, 
2014; Roman et al., 2014) have argued that PACAP may be upstream of BNST CRH and 
therefore may play a prominent role in modulating an extra-hypothalamic CRH system 
implicated in relapse. Prior work has demonstrated that PACAP6-38 ablates the 
production of CRH mRNA: hence, upstream BNST PACAP may be necessary for the 
activity of PVN CRH and other related stress-regions. Alternatively, drug-taking may 
elicit a chronic stress response that activates PACAP in the PBn. May & colleagues 
(Hammack & May, 2015; Missig et al., 2014) described the co-localization of PACAP 
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and calcitonin gene related peptide (CFRP) in the PBn that extend to the BNST and 
amygdala. Chronic relapsing episodes may also depend on this system, as 
neurotransmitter systems implicated in stress-induced relapse appear to be reactivated 
during periods of craving (See et al., 2003; Shaham et al., 2000; Koob & Le Moal, 2008), 
further implicating the idea of an “antireward” system. Indeed, brain reward and stress 
systems activated during periods of drug use are also active during withdrawal (a 
between-system opponent process; Koob & Le Moal, 2008), producing anxiety and 
irritability that comes with discontinued use (due to CRH activation in the extended 
amygdala) and subsequently causing relapse. 
 
Results of previous studies (Miles et al., 2017) are consistent with hypotheses suggesting 
that stress systems have a role in the vulnerability to relapse following stressor exposure 
(Koob & Le Moal, 2008); the BNST has been argued to play a key role in the antireward 
system that may be upregulated by repeated administration of drugs of abuse (Koob & Le 
Moal, 2008; 2001). Stressor exposure may promote relapse by activating some of the 
same antireward circuits associated with withdrawal (Koob, 2015). As mentioned, 
activation of central CRH systems has been suggested as a key step in the recruitment of 
this antireward system by drugs of abuse (Koob & Le Moal, 2005), as PACAP may be an 
upstream regulator of CRH in several stress-related regions such as the BNST. Prior and 
current data suggest that BNST PACAP recruitment may also be a key feature of the 
antireward system that sustains addiction and promotes relapse.  
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To summarize, the negative reinforcement view of addiction proposes that drugs of abuse 
simultaneously activate both brain reward circuits and antireward (stress) circuits that are 
negative in value. As a result, the activation of central and peripheral stress responses 
likely becomes a part of the context of drug taking, creating a “renewal” effect and 
causing a relapse of responding when it occurs again after extinction has been conducted 
in the absence of stressor exposure (the contextual hypothesis of stress-induced 
reinstatement; for review, see Bouton et al., 2014; Schepers, 2017). BNST PACAP 
activation may be a critical component of drug administration that becomes part of the 
context of drug taking that can then produce renewal following extinction. Consistent 
with this argument, cocaine has been shown to activate neurons in the BNST (Singewald 
et al., 2003), and, as Miles et al. (2017) demonstrated, BNST transcript levels were 
significantly increased by cocaine self-administration. Hence, BNST PACAP activation 
may represent part of the context of cocaine self-administration that serves to renew 
cocaine-seeking behavior after extinction.  
 
Prior reports have suggested that activation of CRH receptors in the BNST, but not the 
amygdala, mediates stress-induced reinstatement to drug seeking (Erb & Stewart, 1999). 
At the circuit level, CRH release regulates BNST synaptic activity, both directly and via 
interactions with noradrenergic systems (Kash & Winder, 2006; Nobis et al., 2011). The 
role of BNST CRH and norepinephrine in processes related to addiction is complex and 
may depend on the drug investigated, and it is still unclear how and whether BNST 
PACAP interacts with these other BNST systems to produce the behavioral effects we 
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and others have reported. As noted above, we and others have argued that PACAP is 
upstream of BNST CRH activation and thus may be critical in mediating the effects of 
stress on the reinstatement of extinguished drug-seeking behaviors.  
 
Considerations from quantitative polymerase chain reaction (qPCR) 
 
Miles et al. (2017) showed 10d of cocaine self-administration significantly elevated 
BNST PACAP transcript levels, although PAC1, VPAC1, VPAC2, CRH, and VIP levels 
remained unchanged. Interestingly, BNST PACAP transcript levels were not elevated by 
the reinstatement footshock treatment; however, footshock may lead to peptide release 
that is not reflected in changes in mRNA. We were surprised by the lack of increase in 
CRH transcripts following chronic cocaine self-administration but maintain that upstream 
PACAP release could enhance the excitability of BNST CRH neurons to promote CRH 
release independent of changes in transcript. It may also be possible that BNST PACAP 
targets a specific population of CRH neurons (Marcinkiewcz et al., 2016). We have also 
previously reported that chronic stress upregulates BNST PAC1 receptor transcripts, but 
not VPAC1/VPAC2 transcripts (Lezak et al., 2014; Hammack et al., 2009). Interestingly, 
a recent experiment by Missig et al. (2017) showed that chronic pain elevated PACAP 
transcript levels in the PBn, but not in CeA, BNST, or solitary nucleus (NTS). 
Furthermore, acute stressor exposure or a single day of cocaine self-administration does 
not appear to increase PACAP transcript levels (Figure 1.2; Miles et al., 2017; Lezak et 
al., 2014) indicating that transcript levels may only rise after a period of sustained stress.   
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Considerations from PACAP KO studies 
 
PACAP and PAC1 knockout (KO) mice display numerous behavioral abnormalities, 
including decreased social interaction (Ishihama et al., 2010), increased locomotion 
(Hashimoto et al., 2011), decreased anxiety-related behaviors (Hashimoto et al., 2009), 
anorexic tendencies (Nakata et al., 2004), and memory impairment (Hattori et al., 2012), 
indicating a potential role for PACAP signaling in multiple mental disorders. 
Interestingly, PAC1 receptor deficient mice have a normal stress response to acute 
stressor exposure, but chronic stress resulted in heightened attenuation of HPA axis 
activation (Mustafa et al., 2015). Hence, PACAP-PAC1 receptor signaling may occur at 
later timepoints and require prolonged stimuli, such as chronic stressor exposure or 
chronic drug-taking. Few, if any, studies to date have characterized the timing of PACAP 
expression in a model of drug self-administration. However, the idea of a sustained 
stimuli acting on the PACAP system corresponds with data showing that only chronic 
stressor exposure increases BNST PACAP transcripts (Hammack et al., 2009; Lezak et 
al., 2014), and PAC1 receptor endocytosis may be facilitating downstream signaling 
cascades and “holding on” to PACAP molecules to create a sustained physiological 
response.  
6.2. BNST PACAP signaling via ERK 
 
 
Signaling through extracellular signaling related kinase (ERK) activation 
 
In reward-related brain regions, activation of ERK transcriptional pathways and 
subsequent neuronal adaptations lead to cocaine-induced behavioral plasticity 
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(Girault et al., 2007; Valjent et al., 2006). Hence, in the nucleus accumbens and striatum, 
cocaine exposure increased pERK in rats who were cocaine experienced, indicating a 
sensitization by prior drug administration (Yoon et al., 2007; Valjent et al., 2000). 
Consistent with these results, we found an increase in pERK cells in the BNST after 10d 
drug self-administration followed by footshock stress. Interestingly, the heightened levels 
of pERK likely resulted from footshock stress, but only occurred in animals who were 
cocaine experienced, indicating a sensitization of the PACAP/PAC1 system in response 
to cocaine. Furthermore, the presence of ERK signaling on test day (after 20d of 
extinction training) suggests that ongoing ERK signaling in the BNST is related to 
prolonged exposure to a stimulus (10d drug-taking) rather than part of the initial 
plasticity that results from acute stressor exposure or 1d cocaine taking (what we might 
see in cocaine non-responders after footshock stress and vehicle treatment, for example). 
These studies also found evidence that PACAP signaling may mediate BNST ERK 
activation. Indeed, May and colleagues (May et al., 2010; Hammack & May, 2015; May 
& Parsons, 2017) showed that PACAP signaling in HEK EGFP-PAC1R cell culture 
results in elevated ERK activation, and Missig et al. (2017) showed that, in the CeA, 
ERK activation occurred in close proximity to PACAP-immunoreactive fibers. 
Furthermore, intra-CeA PACAP infusion resulted in an increase of pERK cells, 
indicating that PACAP signaling activates pERK in amygdala neurons. Additional 
studies are needed to observe the effect of intra-BNST PACAP infusion on pERK 
expression, although the current studies suggest that prolonged stressor exposure and 
subsequent pERK activation is necessary for stress-induced reinstatement. Hence, we 
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would anticipate an increase in BNST pERK following PACAP or maxadilan infusion. 
Additional studies here showed that pERK activation is necessary for footshock stress to 
reinstate drug-seeking behaviors, as pretreatment with MEK inhibitor PD98059 or 
clathrin-mediated endocytosis inhibitor Pitstop2 reduced stress-induced reinstatement.  
 
Importantly, BNST ERK signaling is likely the site of convergence for multiple peptide 
signaling systems in the extended amygdala, as several other signaling events likely play 
a role in PACAP- or stress-induced behavioral and physiological responding, including 
norepinephrine, dynorphin, orexin and CRH. Here, we suggest that PACAP activates 
ERK through the internalization of PACAP receptors. As mentioned, Merriam et al. 
(2013) demonstrated that PACAP/PAC1 receptor binding induces PAC1 receptor 
internalization which can be blocked using clathrin-mediated endocytosis inhibitor 
Pitstop2 or dynamin I/II inhibitor, dynasore, resulting in diminished ERK activation. 
Here, we extend these findings in a stress-induced reinstatement paradigm in vivo and 
show diminished pERK activation after pretreatment with MEK and endocytosis 
inhibitors. This compliments work done by Missig et al. (2017) demonstrating a possible 
functional role of PAC1 receptor internalization in CeA pain circuits. However, in both 
chronic pain and chronic drug self-administration models, we must be critical of the 
Pistsop2 pretreatment, as endocytosis inhibition is not selective to the PAC1 receptor and 
globally inhibits receptor endocytosis in the region of infusion. In the absence of 
endocytosis inhibition, PAC1 receptor internalization may present a means for sustained 
ERK activation and subsequent long-duration behavioral and physiological effects of 
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PACAP-PAC1 receptor binding. 
 
ERK activation via AC or PLC 
 
PAC1 receptor endocytosis is not the only mechanism by PAC1 receptors stimulate ERK 
phosphorylation. Indeed, differing PAC1 receptor isoforms can be coupled to Gαs or Gαq 
to activate adenylate cyclase (AC) or phospholipase C (PLC), respectively (for review, 
see Hammack & May, 2015). Hence, there are other means by which PAC1 receptor 
activation may mediate the behavioral consequences of stressor exposure. Indeed, both 
drugs of abuse and stressors exert their effects on neurons through a cascade of 
intracellular signaling events (including AC and PLC) that leads to increased calcium 
levels and stimulation of protein kinase C (PKC). Notably, chronic morphine 
administration has been shown to increase activation of the PLC signaling cascade, likely 
by direct action of neurotrophic factors (Bolanos & Nestler, 2004), but the functional 
consequences of PLC activation by chronic drug administration are not well understood. 
However, PLC activation could conceivably contribute to drug-induced neuroplasticity in 
reward-related regions. Since there was no change in pERK expression in cocaine 
responders who received vehicle vs. Pitstop2 treatment with or without footshock 
exposure, we can infer that PAC1 receptor internalization is required for BNST PACAP 
signaling to induce ERK phosphorylation and activate stress-related behavioral responses 
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6.3. Relation to human studies and clinical trials 
 
Several studies have reported that during abstinence from drug use, stress exposure often 
occurs in the presence of contextual cues that had previously been associated with drug 
use (Epstein et al., 2009); these cues may cause an initial lapse in abstinence. 
Additionally, in a similar manner to the drug-cue induced reinstatement (better termed 
“renewal”; see Bouton, 2014), human studies have indicated that stressor exposure can 
lead to cue-induced drug craving (Moran-Santa Maria et al., 2015; Fox et al., 2014; 
Mantsch et al., 2015). Furthermore, Sinha and colleagues (1999; 2001) introduced a 
clinical trial based on the rodent stress-induced reinstatement paradigm. In these trials, 
stressor exposure (guided imagery stress and Trier Social Stress Task) caused increased 
drug craving. Additionally, researchers provided a systemic CRH injection to induce 
physiological (i.e. increased cortisol release) and psychological (i.e. increased anxiety) 
stress responses. Since then, many researchers have examined the effects of different 
drugs on stress-induced relapse (Sinha et al., 2007; Fox et al., 2012; McKee et al., 2014; 
Moran-Santa Maria et al., 2015), but none have observed the potential effect of PACAP 
on stress-induced relapse. 
 
PACAP treatments may locally target BNST PAC1 receptors via systemic injection to 
antagonist receptors and prevent PACAP binding that facilitates stress-related responses 
and, subsequently, stress induced relapse to drug seeking. By blocking BNST PACAP 
activation, PVN CRH activity may be modified, altering responses to stressor exposure. 
Continued research of mechanisms that underlie stress- and drug-cue-induced 
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reinstatement after a period of abstinence may lead to the development of viable 
treatments for relapse prevention.  
 
As mentioned, the limited data in human drug abusers indicate a reliable correlation 
between animal models of reinstatement and drug relapse and craving in humans. As 
research in the field of drug abuse continues, it will remain important to develop practical 
(medication development) and theoretical models to combat substance use. Future 
laboratory-based human models may mimic and complement existing laboratory-based 
rodent models. The potential use of PACAP antagonists as a method to prevent stress-
induced relapse during times of known stressor exposure should be considered. Indeed, it 
will remain important throughout these developmental phases to investigate the 
concordance between human and animal data of stress-induced relapse. 
 
6.4. Summary 
 
PACAP has been widely accepted as a critical neuropeptide in regulating homeostatic 
function, particularly in response to stressor exposure. Indeed, PACAP signaling can 
activate both physiological and behavioral responses to stress. PACAP may, therefore, 
have roles in drug-taking processes, as several phases of addiction have been shown to 
activate stress response systems. In this dissertation, the role of PACAP-PAC1 receptor 
activation was investigated in a stress-induced reinstatement paradigm.  
 
The results of this work and the work of Miles et al. (2017) raise several 
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additional questions. As discussed above, we found heightened levels of PACAP 
transcript in animals who received 10d cocaine, but not in animals who only received a 
single infusion of cocaine. Furthermore, after a period of extinction, footshock exposure 
failed to elicit an increase in PACAP transcript, indicating that PACAP transcript levels 
may return to control levels following a period of extinction. Here, we found that 
maxadilan infusion recapitulated previous findings and mimicked stressor exposure to 
increase drug-seeking in a test for reinstatement, but the time course for 
PACAP/maxadilan actions on PAC1 receptors is unclear. Hence, future studies might 
seek to determine whether the same signaling events mediating reinstatement (i.e. PAC1 
receptor endocytosis and MEK activation) mediate stress-induced increases of pERK at 
different stages of acquisition and extinction in addition to reinstatement. Furthermore, 
we determined the downstream signaling events mediating stress-induced reinstatement 
to drug seeking, but whether the same activation occurs in response to PACAP-induced 
reinstatement is unknown. Additionally, we hypothesize that PACAP-induced increases 
in pERK expression occurs on CRH neurons within the oval nucleus of the BNST, but 
the location of PAC1 receptors mediating the effects were see in this dissertation are 
unclear. Also unclear is the source of BNST PACAP. Hence, future studies may aim to 
determine where BNST PACAP originates, and how its actions within the oval nucleus 
facilitate reinstatement to drug seeking. The use of PACAP-cre or CRH-cre mice could 
be a powerful tool to answer some of these questions. Indeed, injection of a cre-
dependent virus into the BNST may help us determine which neurons respond to PACAP 
or CRH (respectively) in a test for PACAP- or stress-induced reinstatement. 
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This work demonstrates the involvement of PACAP-PAC1 receptor activation in stress-
induced reinstatement to drug seeking. Indeed, through the PAC1-endocytosis-MEK-
pERK pathway, PACAP seems to potentiate some of the behavioral consequences related 
to stressor exposure after a period of drug-taking. Importantly, the molecular targets 
involved in addiction and relapse and just now being thoroughly investigated. However, 
continued work in this area may explain how circuits become dysregulated, and stay 
dysregulated, in response to stress or drug use to facilitate psychiatric disorders like 
addiction, PTSD, anxiety, and other stress-related disorders. Ultimately, the 
neurobiological targets uncovered through research such as these dissertation 
experiments may identify novel targets for relapse prevention.  
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